drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB00348 | DB08827 | 254 | 990 | [
"DDInter1300",
"DDInter1085"
] | Nitisinone | Lomitapide | Nitisinone is a synthetic reversible inhibitor of 4-hydroxyphenylpyruvate dioxygenase. It is used in the treatment of hereditary tyrosinemia type 1. It is sold under the brand name Orfadin. | Lomitapide is a microsomal triglyceride transfer protein (MTP) inhibitor used in homozygous familial hypercholesterolemia (HoFH) patients. It is marketed under the name Juxtapid (R). | Moderate | 1 | [
[
[
254,
24,
990
]
],
[
[
254,
24,
1080
],
[
1080,
1,
990
]
],
[
[
254,
21,
28903
],
[
28903,
60,
990
]
],
[
[
254,
24,
1362
],
[
1362,
... | [
[
[
"Nitisinone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lomitapide"
]
],
[
[
"Nitisinone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Conivaptan"
],
[
... | Nitisinone may cause a moderate interaction that could exacerbate diseases when taken with Conivaptan and Conivaptan (Compound) resembles Lomitapide (Compound)
Nitisinone (Compound) causes Dry skin (Side Effect) and Dry skin (Side Effect) is caused by Lomitapide (Compound)
Nitisinone may cause a moderate interaction th... |
DB00975 | DB11793 | 1,317 | 738 | [
"DDInter573",
"DDInter1297"
] | Dipyridamole | Niraparib | A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752) | Niraparib is an orally active poly (ADP-ribose) polymerase (PARP) inhibitor. By blocking the enzymes responsible for DNA repair, niraparib induces cytotoxicity in cancer cells. Niraparib is selective towards PARP-1 and PARP-2. First approved by the FDA on March 27, 2017, niraparib is used to treat epithelial ovarian, f... | Moderate | 1 | [
[
[
1317,
24,
738
]
],
[
[
1317,
25,
1213
],
[
1213,
24,
738
]
],
[
[
1317,
64,
1578
],
[
1578,
24,
738
]
],
[
[
1317,
24,
848
],
[
848,
... | [
[
[
"Dipyridamole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niraparib"
]
],
[
[
"Dipyridamole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dasatinib"
],
[
"Dasatini... | Dipyridamole may lead to a major life threatening interaction when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Niraparib
Dipyridamole may lead to a major life threatening interaction when taken with Lepirudin and Lepirudin may cause a moderate inter... |
DB00637 | DB01165 | 1,557 | 1,539 | [
"DDInter128",
"DDInter1325"
] | Astemizole | Ofloxacin | Astemizole is a long-acting, non-sedating second generation antihistamine used in the treatment of allergy symptoms. It was withdrawn from market by the manufacturer in 1999 due to the potential to cause arrhythmias at high doses, especially when when taken with CYP inhibitors or grapefruit juice. | A synthetic fluoroquinolone (fluoroquinolones) antibacterial agent that inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication. | Moderate | 1 | [
[
[
1557,
24,
1539
]
],
[
[
1557,
64,
1176
],
[
1176,
1,
1539
]
],
[
[
1557,
24,
956
],
[
956,
40,
1539
]
],
[
[
1557,
25,
246
],
[
246,
... | [
[
[
"Astemizole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ofloxacin"
]
],
[
[
"Astemizole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Moxifloxacin"
],
[
"Moxifloxa... | Astemizole may lead to a major life threatening interaction when taken with Moxifloxacin and Moxifloxacin (Compound) resembles Ofloxacin (Compound)
Astemizole may cause a moderate interaction that could exacerbate diseases when taken with Norfloxacin and Norfloxacin (Compound) resembles Ofloxacin (Compound)
Astemizole ... |
DB01128 | DB06402 | 918 | 1,079 | [
"DDInter204",
"DDInter1756"
] | Bicalutamide | Telavancin | Bicalutamide is an oral non-steroidal anti-androgen for prostate cancer. It is comprised of a racemic mixture that is a 50:50 composition of the (R)-bicalutamide and (S)-bicalutamide enantionmers. Bicalutamide binds to the androgen receptor. | Telavancin is a semi-synthetic derivative of vanocymycin that has bactericidal activity against Methicillin-resistant Staphylococcus aureus (MRSA) and other gram-positive bacteria. MRSA is an important pathogen capable of causing hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP), and skin and sub... | Moderate | 1 | [
[
[
918,
24,
1079
]
],
[
[
918,
21,
28680
],
[
28680,
60,
1079
]
],
[
[
918,
62,
112
],
[
112,
23,
1079
]
],
[
[
918,
24,
657
],
[
657,
... | [
[
[
"Bicalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Telavancin"
]
],
[
[
"Bicalutamide",
"{u} (Compound) causes {v} (Side Effect)",
"Rash"
],
[
"Rash",
"{u} (Side Effect) is caused by ... | Bicalutamide (Compound) causes Rash (Side Effect) and Rash (Side Effect) is caused by Telavancin (Compound)
Bicalutamide may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Telavancin
... |
DB09049 | DB11732 | 1,135 | 1,097 | [
"DDInter1261",
"DDInter1027"
] | Naloxegol | Lasmiditan | Naloxegol, for "PEGylated naloxol" is a peripherally-selective opioid antagonist developed by AstraZeneca. It was approved by the FDA in September 2014 and is indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non‑cancer pain. The advantage of naloxegol over the opioid antag... | Lasmiditan is an oral medication used in the termination of migraine headaches that was first approved for use in the United States in October 2019.[L9338,L9356] It was also approved by the European Commission on August 17, 2022. Traditionally, the triptan class of anti-migraine medications (e.g. [sumatriptan]) have se... | Moderate | 1 | [
[
[
1135,
24,
1097
]
],
[
[
1135,
23,
971
],
[
971,
63,
1097
]
],
[
[
1135,
62,
478
],
[
478,
24,
1097
]
],
[
[
1135,
25,
384
],
[
384,
... | [
[
[
"Naloxegol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lasmiditan"
]
],
[
[
"Naloxegol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Gilteritinib"
],
[
... | Naloxegol may cause a minor interaction that can limit clinical effects when taken with Gilteritinib and Gilteritinib may cause a moderate interaction that could exacerbate diseases when taken with Lasmiditan
Naloxegol may cause a minor interaction that can limit clinical effects when taken with Nilotinib and Nilotinib... |
DB00279 | DB09104 | 1,152 | 286 | [
"DDInter1074",
"DDInter1118"
] | Liothyronine | Magnesium hydroxide | Liothyronine is a thyroidal hormone T3 which is normally produced by the thyroid gland in a ratio 4:1 when compared with T4: T3. Liothyronine is the active form of thyroxine which is composed in a basic chemical structure by a tyrosine with bound iodine. The exogenous liothyronine product was developed by King Pharmace... | Magnesium hydroxide is an inorganic compound. It is naturally found as the mineral brucite. Magnesium hydroxide can be used as an antacid or a laxative in either an oral liquid suspension or chewable tablet form. Additionally, magnesium hydroxide has smoke suppressing and flame retardant properties and is thus used com... | Moderate | 1 | [
[
[
1152,
24,
286
]
],
[
[
1152,
24,
1482
],
[
1482,
23,
286
]
],
[
[
1152,
62,
88
],
[
88,
23,
286
]
],
[
[
1152,
23,
772
],
[
772,
... | [
[
[
"Liothyronine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Liothyronine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Digitoxin"
... | Liothyronine may cause a moderate interaction that could exacerbate diseases when taken with Digitoxin and Digitoxin may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide
Liothyronine may cause a minor interaction that can limit clinical effects when taken with Metoprolol and... |
DB06691 | DB09488 | 849 | 103 | [
"DDInter1155",
"DDInter23"
] | Mepyramine | Acrivastine | Mepyramine, or pyrilamine, targets the H1 receptor. It is a first generation antihistamine. However, it rapidly permeates the brain and so often causes drowsiness as a side effect. It has been found in over-the-counter combination products for colds and menstrual symptoms, but is considered to be an unapproved prescrip... | Acrivastine is a triprolidine analog antihistamine indicated for the treatment of allergies and hay fever. As an H1 receptor antagonist, it functions by blocking the action of histamine at this receptor thereby preventing the symptoms associated with histamine release such as pruritis, vasodilation, hypotension, edema,... | Moderate | 1 | [
[
[
849,
24,
103
]
],
[
[
849,
23,
771
],
[
771,
62,
103
]
],
[
[
849,
63,
1405
],
[
1405,
24,
103
]
],
[
[
849,
24,
573
],
[
573,
2... | [
[
[
"Mepyramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acrivastine"
]
],
[
[
"Mepyramine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Hyaluronidase"
],
[
... | Mepyramine may cause a minor interaction that can limit clinical effects when taken with Hyaluronidase and Hyaluronidase may cause a minor interaction that can limit clinical effects when taken with Acrivastine
Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Cyclobenzaprine an... |
DB00476 | DB08938 | 109 | 1,384 | [
"DDInter608",
"DDInter1112"
] | Duloxetine | Magaldrate | Duloxetine is a dual serotonin and norepinephrine reuptake inhibitor.[label] It was originally discovered in 1993 and developed by Eli Lilly and Company as LY248686. Duloxetine first received approval from the FDA in August, 2004 as Cymbalta for the treatment of Major Depressive Disorder. It has since received approval... | Magaldrate is an antacid drug used for the treatment of esophagitis, duodenal and gastric ulcers, and gastroesophageal reflux. Magaldrate has been discontinued in the US market. | Minor | 0 | [
[
[
109,
23,
1384
]
],
[
[
109,
24,
752
],
[
752,
23,
1384
]
],
[
[
109,
23,
1559
],
[
1559,
23,
1384
]
],
[
[
109,
63,
1018
],
[
1018,
... | [
[
[
"Duloxetine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magaldrate"
]
],
[
[
"Duloxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cimetidine"
],
[
... | Duloxetine may cause a moderate interaction that could exacerbate diseases when taken with Cimetidine and Cimetidine may cause a minor interaction that can limit clinical effects when taken with Magaldrate
Duloxetine may cause a minor interaction that can limit clinical effects when taken with Famotidine and Famotidine... |
DB01009 | DB09268 | 935 | 1,662 | [
"DDInter1009",
"DDInter1464"
] | Ketoprofen | Picosulfuric acid | Ketoprofen, a propionic acid derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with analgesic and antipyretic properties. | Picosulfuric acid is found in laxative products. Sodium picosulfate is a used to treat constipation or induce colon cleansing to prepare the large bowels before colonoscopy or surgery. The combination product containing sodium picosulfate and magnesium citrate was introduced to the Canadian market in 2005 and has been ... | Moderate | 1 | [
[
[
935,
24,
1662
]
],
[
[
935,
23,
16
],
[
16,
23,
1662
]
],
[
[
935,
25,
1618
],
[
1618,
24,
1662
]
],
[
[
935,
63,
91
],
[
91,
24... | [
[
[
"Ketoprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
]
],
[
[
"Ketoprofen",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Linaclotide"
],
... | Ketoprofen may cause a minor interaction that can limit clinical effects when taken with Linaclotide and Linaclotide may cause a minor interaction that can limit clinical effects when taken with Picosulfuric acid
Ketoprofen may lead to a major life threatening interaction when taken with Cabozantinib and Cabozantinib m... |
DB01105 | DB01110 | 222 | 86 | [
"DDInter1665",
"DDInter1209"
] | Sibutramine | Miconazole | Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity. It is a centrally acting stimulant chemically related to amphetamines thus it is classified as a Schedule IV controlled sub... | Miconazole is a broad-spectrum azole antifungal with some activity against Gram-positive bacteria as well. It is widely used to treat mucosal yeast infections, including both oral and vaginal infections; although intravenous miconazole is no longer available, a wide variety of suppositories, creams, gels, and tablet-ba... | Minor | 0 | [
[
[
222,
23,
86
]
],
[
[
222,
6,
8374
],
[
8374,
45,
86
]
],
[
[
222,
21,
29081
],
[
29081,
60,
86
]
],
[
[
222,
25,
318
],
[
318,
6... | [
[
[
"Sibutramine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Miconazole"
]
],
[
[
"Sibutramine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",... | Sibutramine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Miconazole (Compound)
Sibutramine (Compound) causes Angioedema (Side Effect) and Angioedema (Side Effect) is caused by Miconazole (Compound)
Sibutramine may lead to a major life threatening interaction when taken with Escitalopram and Escitalopram... |
DB00675 | DB00743 | 888 | 808 | [
"DDInter1744",
"DDInter792"
] | Tamoxifen | Gadobenic acid | Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations.[A1025,L7799,L7802] Tamoxifen is used alone or as an adjuvant in these treatments.[L7799,L7802] Tamoxifen may no longer be the preferred treatment ... | Gadobenic acid, usually available in the salt form gadobenate dimeglumine, is a linear MRI gadolinium-based contrast agent (GBCA) used primarily for MR imaging of the liver. It differs from other GBCAs due to the benzene ring that confers weak protein binding, thus leading to an increased R1 and R2 relaxivity. As gadob... | Moderate | 1 | [
[
[
888,
24,
808
]
],
[
[
888,
21,
28703
],
[
28703,
60,
808
]
],
[
[
888,
25,
1327
],
[
1327,
63,
808
]
],
[
[
888,
63,
322
],
[
322,
... | [
[
[
"Tamoxifen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gadobenic acid"
]
],
[
[
"Tamoxifen",
"{u} (Compound) causes {v} (Side Effect)",
"Pruritus"
],
[
"Pruritus",
"{u} (Side Effect) is caus... | Tamoxifen (Compound) causes Pruritus (Side Effect) and Pruritus (Side Effect) is caused by Gadobenic acid (Compound)
Tamoxifen may lead to a major life threatening interaction when taken with Saquinavir and Saquinavir may cause a moderate interaction that could exacerbate diseases when taken with Gadobenic acid
Tamoxif... |
DB00365 | DB00987 | 839 | 1,224 | [
"DDInter842",
"DDInter460"
] | Grepafloxacin | Cytarabine | Grepafloxacin is an oral broad-spectrum quinoline antibacterial agent used to treat bacterial infections. Due to the QTc-prolonging potential, as indicated by the changes in the QT interval on the electrocardiogram, and the risk for cardiovascular adverse events, grepafloxacin was withdrawn in the United States. | A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant p... | Minor | 0 | [
[
[
839,
23,
1224
]
],
[
[
839,
25,
322
],
[
322,
24,
1224
]
],
[
[
839,
62,
134
],
[
134,
24,
1224
]
],
[
[
839,
24,
896
],
[
896,
... | [
[
[
"Grepafloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cytarabine"
]
],
[
[
"Grepafloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Epirubicin"
],
[
"Epirub... | Grepafloxacin may lead to a major life threatening interaction when taken with Epirubicin and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Cytarabine
Grepafloxacin may cause a minor interaction that can limit clinical effects when taken with Vinorelbine and Vinorelbine may ... |
DB01118 | DB14723 | 33 | 159 | [
"DDInter76",
"DDInter1026"
] | Amiodarone | Larotrectinib | Amiodarone is a benzofuran derivative, anti-arrhythmic drug used commonly in a variety of settings. Most known for its approved indication in life-threatening ventricular arrhythmias, it is also used off-label in the outpatient and inpatient setting for atrial fibrillation. Because of its ability to cause serious toxic... | Larotrectinib is an orally administered inhibitor of tropomyosin receptor kinase (Trk), a receptor tyrosine kinase activated by neurotrophins which is mutated in a variety of cancer cell types and plays an important role in tumor cell growth and survival. Upon administration, larotrectinib binds to Trk, thereby prevent... | Moderate | 1 | [
[
[
33,
24,
159
]
],
[
[
33,
23,
466
],
[
466,
23,
159
]
],
[
[
33,
63,
63
],
[
63,
24,
159
]
],
[
[
33,
24,
98
],
[
98,
24,
1... | [
[
[
"Amiodarone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
]
],
[
[
"Amiodarone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Darolutamide"
],
[... | Amiodarone may cause a minor interaction that can limit clinical effects when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Larotrectinib
Amiodarone may cause a moderate interaction that could exacerbate diseases when taken with Teniposide and Ten... |
DB00304 | DB01309 | 1,657 | 1,254 | [
"DDInter508",
"DDInter933"
] | Desogestrel | Insulin glulisine | Desogestrel, a prodrug, is a third generation progestogen and hence, a member of the gonane family which was largely used in Europe before being approved in the US and Canada. It was firstly generated from a study that showed that 11-beta and 11-alkylidene substituent in nortestosterone can enhance the biological activ... | Insulin glulisine is a short-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas... | Moderate | 1 | [
[
[
1657,
24,
1254
]
],
[
[
1657,
24,
1094
],
[
1094,
63,
1254
]
],
[
[
1657,
24,
1645
],
[
1645,
24,
1254
]
],
[
[
1657,
1,
566
],
[
566,... | [
[
[
"Desogestrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glulisine"
]
],
[
[
"Desogestrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metreleptin"
]... | Desogestrel may cause a moderate interaction that could exacerbate diseases when taken with Metreleptin and Metreleptin may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine
Desogestrel may cause a moderate interaction that could exacerbate diseases when taken with Metformin ... |
DB00363 | DB00804 | 695 | 1,507 | [
"DDInter419",
"DDInter543"
] | Clozapine | Dicyclomine | Clozapine is a tricyclic dibenzodiazepine, classified as an atypical antipsychotic agent. Clozapine displays affinity to various neuroreceptors with a particularly low affinity to the dopamine receptors, thus breaking the mold of first-generation antipsychotics and deeming it "atypical".. This low affinity to dopamine ... | Dicyclomine is a muscarinic M1, M3, and M2 receptor antagonist as well as a non-competitive inhibitor of histamine and bradykinin used to treat spasms of the intestines seen in functional bowel disorder and irritable bowel syndrome.[A6556,A182555,A234659,L7967] Though it is commonly prescribed, its recommendation may h... | Moderate | 1 | [
[
[
695,
24,
1507
]
],
[
[
695,
6,
2720
],
[
2720,
45,
1507
]
],
[
[
695,
24,
1021
],
[
1021,
63,
1507
]
],
[
[
695,
24,
1594
],
[
1594,
... | [
[
[
"Clozapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dicyclomine"
]
],
[
[
"Clozapine",
"{u} (Compound) binds {v} (Gene)",
"CHRM3"
],
[
"CHRM3",
"{u} (Gene) is bound by {v} (Compound)",
... | Clozapine (Compound) binds CHRM3 (Gene) and CHRM3 (Gene) is bound by Dicyclomine (Compound)
Clozapine may cause a moderate interaction that could exacerbate diseases when taken with Pramlintide and Pramlintide may cause a moderate interaction that could exacerbate diseases when taken with Dicyclomine
Clozapine may caus... |
DB08899 | DB08901 | 129 | 1,468 | [
"DDInter649",
"DDInter1492"
] | Enzalutamide | Ponatinib | Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line ... | Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012. | Moderate | 1 | [
[
[
129,
24,
1468
]
],
[
[
129,
64,
478
],
[
478,
24,
1468
]
],
[
[
129,
6,
12523
],
[
12523,
45,
1468
]
],
[
[
129,
7,
5562
],
[
5562,
... | [
[
[
"Enzalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ponatinib"
]
],
[
[
"Enzalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nilotinib"
],
[
"Nilotini... | Enzalutamide may lead to a major life threatening interaction when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib
Enzalutamide (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Ponatinib (Compound)
Enzalutamide (Compound) upregulat... |
DB00586 | DB00687 | 1,512 | 870 | [
"DDInter537",
"DDInter747"
] | Diclofenac | Fludrocortisone | Diclofenac is a phenylacetic acid derivative and non-steroidal anti-inflammatory drug (NSAID).[label] NSAIDs inhibit cyclooxygenase (COX)-1 and-2 which are the enzyme responsible for producing prostaglandins (PGs). PGs contribute to inflammation and pain signalling. Diclofenac, like other NSAIDs, is often used as first... | Fludrocortisone is a synthetic mineralocorticoid used in conjunction with [hydrocortisone] to replace missing endogenous corticosteroids in patients with adrenal insufficiency.[A187169,A187187] It is functionally similar to [aldosterone], the body's primary endogenous mineralocorticoid, and is structurally analogous to... | Moderate | 1 | [
[
[
1512,
24,
870
]
],
[
[
1512,
24,
1220
],
[
1220,
40,
870
]
],
[
[
1512,
63,
251
],
[
251,
40,
870
]
],
[
[
1512,
63,
443
],
[
443,
... | [
[
[
"Diclofenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludrocortisone"
]
],
[
[
"Diclofenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
],
... | Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone (Compound) resembles Fludrocortisone (Compound)
Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Betamethasone and Betamethasone (Compound) resembles Fludr... |
DB09118 | DB12941 | 1,580 | 466 | [
"DDInter1711",
"DDInter481"
] | Stiripentol | Darolutamide | Stiripentol is an antiepileptic agent that is an aromatic allylic alcohol drug, which makes it structurally unique from other antiepileptic drugs.[A19740, A250825] The clinical development and marketing of stiripentol were first delayed due to the drug's potent inhibitory effects on hepatic cytochrome P450 (CYP) enzyme... | Darolutamide is a nonsteroidal androgen receptor antagonist for the treatment of castrate-resistant, non-metastatic prostate cancer (nmCRPC). This condition occurs in the majority of patients with advanced prostate cancer who have been treated with androgen receptor antagonists. Though prior treatment for prostate canc... | Minor | 0 | [
[
[
1580,
23,
466
]
],
[
[
1580,
63,
1374
],
[
1374,
23,
466
]
],
[
[
1580,
24,
351
],
[
351,
23,
466
]
],
[
[
1580,
25,
484
],
[
484,
... | [
[
[
"Stiripentol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Darolutamide"
]
],
[
[
"Stiripentol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abiraterone"
],
[... | Stiripentol may cause a moderate interaction that could exacerbate diseases when taken with Abiraterone and Abiraterone may cause a minor interaction that can limit clinical effects when taken with Darolutamide
Stiripentol may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and Ri... |
DB00242 | DB14409 | 1,064 | 1,129 | [
"DDInter392",
"DDInter867"
] | Cladribine | Human adenovirus e serotype 4 strain cl-68578 antigen | An antineoplastic agent used in the treatment of lymphoproliferative diseases including hairy-cell leukemia. | Human adenovirus e serotype 4 strain cl-68578 antigen is a vaccine. | Moderate | 1 | [
[
[
1064,
24,
1129
]
],
[
[
1064,
64,
1057
],
[
1057,
24,
1129
]
],
[
[
1064,
25,
1683
],
[
1683,
24,
1129
]
],
[
[
1064,
36,
1238
],
[
12... | [
[
[
"Cladribine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Human adenovirus e serotype 4 strain cl-68578 antigen"
]
],
[
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
... | Cladribine may lead to a major life threatening interaction when taken with Etanercept and Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Human adenovirus e serotype 4 strain cl-68578 antigen
Cladribine may lead to a major life threatening interaction when taken with Ustekinu... |
DB00227 | DB00446 | 1,463 | 597 | [
"DDInter1098",
"DDInter351"
] | Lovastatin | Chloramphenicol | Lovastatin, also known as the brand name product Mevacor, is a lipid-lowering drug and fungal metabolite derived synthetically from a fermentation product of _Aspergillus terreus_. Originally named Mevinolin, lovastatin belongs to the statin class of medications, which are used to lower the risk of cardiovascular disea... | An antibiotic first isolated from cultures of _Streptomyces venezuelae_ in 1947 but now produced synthetically. It has a relatively simple structure and was the first broad-spectrum antibiotic to be discovered. It acts by interfering with bacterial protein synthesis and is mainly bacteriostatic. (From Martindale, The E... | Moderate | 1 | [
[
[
1463,
24,
597
]
],
[
[
1463,
6,
7524
],
[
7524,
45,
597
]
],
[
[
1463,
18,
7448
],
[
7448,
46,
597
]
],
[
[
1463,
7,
3466
],
[
3466,
... | [
[
[
"Lovastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chloramphenicol"
]
],
[
[
"Lovastatin",
"{u} (Compound) binds {v} (Gene)",
"CYP3A5"
],
[
"CYP3A5",
"{u} (Gene) is bound by {v} (Compou... | Lovastatin (Compound) binds CYP3A5 (Gene) and CYP3A5 (Gene) is bound by Chloramphenicol (Compound)
Lovastatin (Compound) downregulates MOK (Gene) and MOK (Gene) is upregulated by Chloramphenicol (Compound)
Lovastatin (Compound) upregulates CCNA1 (Gene) and CCNA1 (Gene) is upregulated by Chloramphenicol (Compound)
Lovas... |
DB00446 | DB01175 | 597 | 318 | [
"DDInter351",
"DDInter672"
] | Chloramphenicol | Escitalopram | An antibiotic first isolated from cultures of _Streptomyces venezuelae_ in 1947 but now produced synthetically. It has a relatively simple structure and was the first broad-spectrum antibiotic to be discovered. It acts by interfering with bacterial protein synthesis and is mainly bacteriostatic. (From Martindale, The E... | Escitalopram is a selective serotonin re-uptake inhibitor (SSRI) and the S-enantiomer of racemic [citalopram]. It is used to restore serotonergic function in the treatment of depression and anxiety.[L8513,L8516,L8522] Escitalopram is approximately 150 times more potent than citalopram’s R-enantiomer and is responsible ... | Minor | 0 | [
[
[
597,
23,
318
]
],
[
[
597,
62,
1230
],
[
1230,
1,
318
]
],
[
[
597,
6,
8374
],
[
8374,
45,
318
]
],
[
[
597,
18,
3741
],
[
3741,
... | [
[
[
"Chloramphenicol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Escitalopram"
]
],
[
[
"Chloramphenicol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Citalopram"
],
... | Chloramphenicol may cause a minor interaction that can limit clinical effects when taken with Citalopram and Citalopram (Compound) resembles Escitalopram (Compound)
Chloramphenicol (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Escitalopram (Compound)
Chloramphenicol (Compound) downregulates OXA1L (Gene) ... |
DB11130 | DB13909 | 407 | 1,277 | [
"DDInter1344",
"DDInter214"
] | Opium | Bismuth subgallate | Opium is the first substance of the diverse group of the opiates. It has been known for a long time, and the first evidence of a poppy culture dates from 5 thousand years by the Sumerians. During the years, opium was used as a sedative and hypnotic, but it was determined to be addictive. Opium is extracted from _Papave... | Bismuth subgallate is a yellow colored substance that presents as an odorless powder that undergoes discoloration when exposed to sunlight. It is a heavy metal salt of gallic acid that is highly insoluble and poorly absorbed. Possessing protective effects on the gastric mucosa, strong astringent effects, and not as yet... | Moderate | 1 | [
[
[
407,
24,
1277
]
],
[
[
407,
63,
475
],
[
475,
24,
1277
]
],
[
[
407,
24,
1399
],
[
1399,
62,
964
],
[
964,
24,
1277
]
],
[
[
407,
... | [
[
[
"Opium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bismuth subgallate"
]
],
[
[
"Opium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Morphine"
],
[
... | Opium may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Bismuth subgallate
Opium may cause a moderate interaction that could exacerbate diseases when taken with Lithium carbonate and Lithi... |
DB01115 | DB01285 | 336 | 708 | [
"DDInter1291",
"DDInter445"
] | Nifedipine | Corticotropin | Nifedipine, or BAY a 1040, is a first generation dihydropyridine L-type calcium channel blocker, similar to [nicardipine].[A190210,A190273,A175390,L11383] Nifedipine was developed by Bayer and first described in the literature, along with other dihydropyridines, in 1972.[A175390,A190276] Since nifedipine's development,... | Corticotropin (ACTH or adrenocorticotropic hormone) is a polypeptide hormone produced and secreted by the pituitary gland. It is an important player in the hypothalamic-pituitary-adrenal axis. | Moderate | 1 | [
[
[
336,
24,
708
]
],
[
[
336,
63,
1324
],
[
1324,
24,
708
]
],
[
[
336,
24,
1450
],
[
1450,
63,
708
]
],
[
[
336,
62,
1031
],
[
1031,
... | [
[
[
"Nifedipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Corticotropin"
]
],
[
[
"Nifedipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Troglitazone"
],
... | Nifedipine may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone and Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Corticotropin
Nifedipine may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin ... |
DB08886 | DB11827 | 637 | 433 | [
"DDInter126",
"DDInter669"
] | Asparaginase Erwinia chrysanthemi | Ertugliflozin | Asparaginase _Erwinia chrysanthemi_ is an asparaginase-specific enzyme derived from _Erwinia_ _chrysanthemi_ used as an anticancer agent. It works by depleting the stores of an important amino acid called asparagine, which is involved in DNA synthesis and cell survival of malignant cells, leading to cell death. L-aspar... | Ertugliflozin is a sodium-dependent glucose cotransporter-2 (SGLT2) inhibitor used to treat type II diabetes mellitus. It works to block glucose reabsorption from the glomerulus. Ertugliflozin was first approved by the FDA in December 2017.[A261951, L1132] It was also approved by the European Commission in March 2018. | Moderate | 1 | [
[
[
637,
24,
433
]
],
[
[
637,
63,
959
],
[
959,
24,
433
]
],
[
[
637,
24,
1019
],
[
1019,
63,
433
]
],
[
[
637,
24,
1296
],
[
1296,
... | [
[
[
"Asparaginase Erwinia chrysanthemi",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ertugliflozin"
]
],
[
[
"Asparaginase Erwinia chrysanthemi",
"{u} may cause a moderate interaction that could exacerbate diseases when ta... | Asparaginase Erwinia chrysanthemi may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin
Asparaginase Erwinia chrysanthemi may cause a moderate interaction that could exacerbate... |
DB00252 | DB11581 | 362 | 1,456 | [
"DDInter1460",
"DDInter1926"
] | Phenytoin | Venetoclax | Phenytoin is classified as a hydantoin derivative and despite its narrow therapeutic index, it is one of the most commonly used anticonvulsants.[A33595,A188832,A189219] Since it's introduction about 80 years ago, phenytoin has not only been established as an effective anti-epileptic, but has also been investigated for ... | Venetoclax is a BCL-2 inhibitor that was initially approved by the FDA in April 2016 [FDA label]. Proteins in the B cell CLL/lymphoma 2 (BCL-2) family are important regulators of the apoptotic (programmed cell death) process , . Venetoclax is used to treat chronic lymphocytic leukemia (CLL) and certain types of small l... | Major | 2 | [
[
[
362,
25,
1456
]
],
[
[
362,
25,
1135
],
[
1135,
23,
1456
]
],
[
[
362,
24,
259
],
[
259,
24,
1456
]
],
[
[
362,
25,
1476
],
[
1476,
... | [
[
[
"Phenytoin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Venetoclax"
]
],
[
[
"Phenytoin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
"{u} may c... | Phenytoin may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Venetoclax
Phenytoin may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept and Rilonacept may cause a mode... |
DB11348 | DB12147 | 1,065 | 241 | [
"DDInter279",
"DDInter661"
] | Calcium Phosphate | Erdafitinib | Calcium phosphate is typically available as an over the counter supplement, antacid, or as an added ingredient in some toothpastes [FDA Label]. | In early April of 2019, the US FDA approved Janssen Pharmaceutical Companies' brand name Balversa (erdafitinib) as the first-ever fibroblast growth factor receptor (FGFR) kinase inhibitor indicated for patients with locally advanced or metastatic urothelial carcinoma, with susceptible FGFR3 or FGFR2 genetic alterations... | Major | 2 | [
[
[
1065,
25,
241
]
],
[
[
1065,
24,
943
],
[
943,
62,
1135
],
[
1135,
24,
241
]
],
[
[
1065,
63,
1014
],
[
1014,
24,
1196
],
[
1196,
25... | [
[
[
"Calcium Phosphate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Erdafitinib"
]
],
[
[
"Calcium Phosphate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sarecycline"
],
[
... | Calcium Phosphate may cause a moderate interaction that could exacerbate diseases when taken with Sarecycline and Sarecycline may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may cause a moderate interaction that could exacerbate diseases when taken with Erdafitinib
... |
DB01319 | DB11827 | 34 | 433 | [
"DDInter777",
"DDInter669"
] | Fosamprenavir | Ertugliflozin | Fosamprenavir is a prodrug of amprenavir, an inhibitor of human immunodeficiency virus (HIV) protease. | Ertugliflozin is a sodium-dependent glucose cotransporter-2 (SGLT2) inhibitor used to treat type II diabetes mellitus. It works to block glucose reabsorption from the glomerulus. Ertugliflozin was first approved by the FDA in December 2017.[A261951, L1132] It was also approved by the European Commission in March 2018. | Moderate | 1 | [
[
[
34,
24,
433
]
],
[
[
34,
63,
959
],
[
959,
24,
433
]
],
[
[
34,
62,
609
],
[
609,
24,
433
]
],
[
[
34,
64,
175
],
[
175,
24,
... | [
[
[
"Fosamprenavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ertugliflozin"
]
],
[
[
"Fosamprenavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
],
... | Fosamprenavir may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin
Fosamprenavir may cause a minor interaction that can limit clinical effects when taken with Clarithromycin a... |
DB00712 | DB01088 | 1,274 | 714 | [
"DDInter763",
"DDInter908"
] | Flurbiprofen | Iloprost | Flurbiprofen, a propionic acid derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with antipyretic and analgesic activity. Oral formulations of flurbiprofen may be used for the symptomatic treatment of rheumatoid arthritis, osteoarthritis and anklylosing spondylitis. Flurbiprofen may also be used topically p... | Iloprost is a mimetic of prostacyclin (PGI2; epoprostenol). Iloprost consists of a mixture of the 4R and 4S diastereoisomers at a ratio of approximately 53:47. It is a potent vasodilator with reported anti-thrombotic properties. | Moderate | 1 | [
[
[
1274,
24,
714
]
],
[
[
1274,
63,
1638
],
[
1638,
24,
714
]
],
[
[
1274,
24,
1479
],
[
1479,
24,
714
]
],
[
[
1274,
24,
318
],
[
318,
... | [
[
[
"Flurbiprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iloprost"
]
],
[
[
"Flurbiprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trandolapril"
],
... | Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Trandolapril and Trandolapril may cause a moderate interaction that could exacerbate diseases when taken with Iloprost
Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Acetylsalicylic... |
DB06448 | DB08895 | 171 | 976 | [
"DDInter1087",
"DDInter1825"
] | Lonafarnib | Tofacitinib | Hutchinson-Gilford progeria syndrome (HGPS) is a rare autosomal dominant disorder estimated to affect approximately one in 20 million individuals resulting in adverse symptoms associated with premature ageing: skeletal dysplasia, joint contractures, atherosclerosis, myocardial fibrosis/dysfunction, scleroderma-like cut... | Tofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that affect hematopoiesis and immune cell function. It is approved by the FDA for treatment of moderate to severe rheumatoid arthritis that responds inadequately to methotrexate or in those who are intolerant ... | Major | 2 | [
[
[
171,
25,
976
]
],
[
[
171,
63,
660
],
[
660,
24,
976
]
],
[
[
171,
25,
214
],
[
214,
63,
976
]
],
[
[
171,
64,
723
],
[
723,
24,... | [
[
[
"Lonafarnib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
]
],
[
[
"Lonafarnib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Esomeprazole"
],
[
"Esomepr... | Lonafarnib may cause a moderate interaction that could exacerbate diseases when taken with Esomeprazole and Esomeprazole may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib
Lonafarnib may lead to a major life threatening interaction when taken with Fostamatinib and Fostamatinib m... |
DB04953 | DB09075 | 495 | 498 | [
"DDInter708",
"DDInter621"
] | Ezogabine | Edoxaban | Ezogabine (D23129) is a close structural analog of the centrally acting analgesic flupitrine. It is a neuronal potassium channel opener being developed as a first-in-class antiepileptic drug (AED) and is currently being studied in Phase 3 trials as an adjunctive treatment for partial-onset seizures in adult patients wi... | Edoxaban is a member of the Novel Oral Anti-Coagulants (NOACs) class of drugs, and is a rapidly acting, oral, selective factor Xa inhibitor. By inhibiting factor Xa, a key protein in the coagulation cascade, edoxaban prevents the stepwise amplification of protein factors needed to form blood clots. It is indicated to r... | Major | 2 | [
[
[
495,
25,
498
]
],
[
[
495,
63,
222
],
[
222,
24,
498
]
],
[
[
495,
24,
129
],
[
129,
24,
498
]
],
[
[
495,
24,
124
],
[
124,
63,... | [
[
[
"Ezogabine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Edoxaban"
]
],
[
[
"Ezogabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
"Sibutramine",... | Ezogabine may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Edoxaban
Ezogabine may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalu... |
DB01217 | DB12010 | 630 | 214 | [
"DDInter95",
"DDInter785"
] | Anastrozole | Fostamatinib | Anastrozole is a non-steroidal aromatase inhibitor (AI), similar to [letrozole], used to decrease circulating estrogen levels in the treatment of postmenopausal women with estrogen-responsive breast cancer. Anastrozole is also related to [exemestane], a steroidal AI, but its non-steroidal nature provides stark advantag... | Fostamatinib has been investigated for the treatment and basic science of Rheumatoid Arthritis and Immune Thrombocytopenic Purpura (ITP). It was approved on April 17, 2018, under the trade name Tavalisse for use in ITP [L2644, FDA Label]. Fostamatinib has also been granted orphan drug status by the FDA . Recently, fost... | Moderate | 1 | [
[
[
630,
24,
214
]
],
[
[
630,
24,
1155
],
[
1155,
24,
214
]
],
[
[
630,
63,
559
],
[
559,
24,
214
]
],
[
[
630,
24,
1155
],
[
1155,
... | [
[
[
"Anastrozole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Anastrozole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tucatinib"
],
[... | Anastrozole may cause a moderate interaction that could exacerbate diseases when taken with Tucatinib and Tucatinib may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Anastrozole may cause a moderate interaction that could exacerbate diseases when taken with Estrone and Estrone... |
DB00134 | DB00852 | 346 | 1,445 | [
"DDInter1171",
"DDInter1545"
] | Methionine | Pseudoephedrine | A sulfur containing essential amino acid that is important in many body functions. It is a chelating agent for heavy metals. | Pseudoephedrine is structurally related to [ephedrine] but exerts a weaker effect on the sympathetic nervous system.[A188820,A188823] Both drugs naturally occur in in ephedra plant which have a history of use in traditional Eastern medicine and were first researched in the west in 1889. The decongestant effect of pseud... | Minor | 0 | [
[
[
346,
23,
1445
]
],
[
[
346,
23,
22
],
[
22,
40,
1445
]
],
[
[
346,
1,
11478
],
[
11478,
21,
29118
],
[
29118,
60,
1445
]
],
[
[
346,
... | [
[
[
"Methionine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Pseudoephedrine"
]
],
[
[
"Methionine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ephedrine"
],
[
... | Methionine may cause a minor interaction that can limit clinical effects when taken with Ephedrine and Ephedrine (Compound) resembles Pseudoephedrine (Compound)
Methionine (Compound) resembles L-Arginine (Compound) and L-Arginine (Compound) causes Tachycardia (Side Effect) and Tachycardia (Side Effect) is caused by Pse... |
DB00563 | DB00900 | 663 | 45 | [
"DDInter1174",
"DDInter544"
] | Methotrexate | Didanosine | Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division. Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division ... | A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. Didanosine is a potent inhibitor of HIV replication, acting as a chain-termi... | Moderate | 1 | [
[
[
663,
24,
45
]
],
[
[
663,
6,
10612
],
[
10612,
45,
45
]
],
[
[
663,
21,
29156
],
[
29156,
60,
45
]
],
[
[
663,
24,
1620
],
[
1620,
... | [
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Didanosine"
]
],
[
[
"Methotrexate",
"{u} (Compound) binds {v} (Gene)",
"SLC22A6"
],
[
"SLC22A6",
"{u} (Gene) is bound by {v} (Compo... | Methotrexate (Compound) binds SLC22A6 (Gene) and SLC22A6 (Gene) is bound by Didanosine (Compound)
Methotrexate (Compound) causes Leukoderma (Side Effect) and Leukoderma (Side Effect) is caused by Didanosine (Compound)
Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Tetracycl... |
DB00322 | DB11988 | 141 | 270 | [
"DDInter742",
"DDInter1321"
] | Floxuridine | Ocrelizumab | An antineoplastic antimetabolite that is metabolized to fluorouracil when administered by rapid injection. Floxuridine is available as a sterile, nonpyrogenic, lyophilized powder for reconstitution. When administered by slow, continuous, intra-arterial infusion, it is converted to floxuridine monophosphate. It has been... | Ocrelizumab is a CD20-directed cytolytic antibody indicated for the treatment of patients with primary progressive or relapsing forms of multiple sclerosis (MS). It is a second-generation recombinant humanized monoclonal IgG1 antibody that selectively targets B-cells that express the CD20 antigen. Compared to non-human... | Moderate | 1 | [
[
[
141,
24,
270
]
],
[
[
141,
63,
1461
],
[
1461,
23,
270
]
],
[
[
141,
24,
134
],
[
134,
24,
270
]
],
[
[
141,
1,
1083
],
[
1083,
... | [
[
[
"Floxuridine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
]
],
[
[
"Floxuridine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[
... | Floxuridine may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Ocrelizumab
Floxuridine may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine and Vinore... |
DB11827 | DB12015 | 433 | 1,033 | [
"DDInter669",
"DDInter53"
] | Ertugliflozin | Alpelisib | Ertugliflozin is a sodium-dependent glucose cotransporter-2 (SGLT2) inhibitor used to treat type II diabetes mellitus. It works to block glucose reabsorption from the glomerulus. Ertugliflozin was first approved by the FDA in December 2017.[A261951, L1132] It was also approved by the European Commission in March 2018. | Alpelisib is a phosphatidylinositol 3-kinase (PI3K) inhibitor with potent antitumor activity. It works by selectively inhibiting class I PI3K p110α , which is the catalytic subunit of PI3K, a lipid kinase that plays a role in various biological processes, including proliferation, survival, differentiation, and metaboli... | Moderate | 1 | [
[
[
433,
24,
1033
]
],
[
[
433,
63,
1254
],
[
1254,
24,
1033
]
],
[
[
433,
24,
1654
],
[
1654,
63,
1033
]
],
[
[
433,
24,
255
],
[
255,
... | [
[
[
"Ertugliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alpelisib"
]
],
[
[
"Ertugliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glulisine"
... | Ertugliflozin may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine and Insulin glulisine may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Ertugliflozin may cause a moderate interaction that could exacerbate diseases when taken with So... |
DB09074 | DB09123 | 1,362 | 1,525 | [
"DDInter1327",
"DDInter546"
] | Olaparib | Dienogest | Olaparib is a selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, PARP1 and PARP2.[L41100, L40908, L43792] PARP inhibitors represent a novel class of anti-cancer therapy and they work by taking advantage of a defect in DNA repair in cancer cells with BRCA mutations and inducing cell death. Ol... | Dienogest is an orally-active semisynthetic progestogen which also possesses the properties of 17α-hydroxyprogesterone. It is a derivative of 19-nortestosterone and has antiandrogenic properties. It is primarily used as a contraceptive in combination with ethinylestradiol, or in other combination form pills approved in... | Moderate | 1 | [
[
[
1362,
24,
1525
]
],
[
[
1362,
64,
1064
],
[
1064,
24,
1525
]
],
[
[
1362,
63,
980
],
[
980,
24,
1525
]
],
[
[
1362,
24,
484
],
[
484,
... | [
[
[
"Olaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dienogest"
]
],
[
[
"Olaparib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
],
[
"Cladribine",
... | Olaparib may lead to a major life threatening interaction when taken with Cladribine and Cladribine may cause a moderate interaction that could exacerbate diseases when taken with Dienogest
Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Tocilizumab and Tocilizumab may cause a m... |
DB01067 | DB01191 | 959 | 1,039 | [
"DDInter826",
"DDInter518"
] | Glipizide | Dexfenfluramine | Glipizide is an oral hypoglycemic agent in the second-generation sulfonylurea drug class that is used to control blood sugar levels in patients with type 2 diabetes mellitus. It was first introduced in 1984 and is available in various countries including Canada and the U.S. According to the 2018 Clinical Practice Guide... | Dexfenfluramine, also marketed under the name Redux, is a serotoninergic anorectic drug. For a fairly limited time during the middle of the nineties, the US FDA had approved it for use in managing weight loss. However, following multiple concerns about the cardiovascular side-effects of the drug, such approval was with... | Moderate | 1 | [
[
[
959,
24,
1039
]
],
[
[
959,
24,
1529
],
[
1529,
64,
1039
]
],
[
[
959,
6,
6017
],
[
6017,
45,
1039
]
],
[
[
959,
18,
4360
],
[
4360,
... | [
[
[
"Glipizide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexfenfluramine"
]
],
[
[
"Glipizide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metamfetamine"
],
... | Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Metamfetamine and Metamfetamine may lead to a major life threatening interaction when taken with Dexfenfluramine
Glipizide (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Dexfenfluramine (Compound)
Glipizide (Compound... |
DB00087 | DB14409 | 599 | 1,129 | [
"DDInter41",
"DDInter867"
] | Alemtuzumab | Human adenovirus e serotype 4 strain cl-68578 antigen | Alemtuzumab is a humanized monoclonal antibody specific to lymphocyte antigens. It is a recombinant DNA-derived humanized monoclonal antibody (Campath-1H) that is directed against the 21-28 kD cell surface glycoprotein, CD52. The Campath-1H antibody is an IgG1 kappa with the human variable framework and constant region... | Human adenovirus e serotype 4 strain cl-68578 antigen is a vaccine. | Moderate | 1 | [
[
[
599,
24,
1129
]
],
[
[
599,
63,
1057
],
[
1057,
24,
1129
]
],
[
[
599,
24,
1683
],
[
1683,
24,
1129
]
],
[
[
599,
25,
1259
],
[
1259,
... | [
[
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Human adenovirus e serotype 4 strain cl-68578 antigen"
]
],
[
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken ... | Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Etanercept and Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Human adenovirus e serotype 4 strain cl-68578 antigen
Alemtuzumab may cause a moderate interaction that could exacerbate d... |
DB00893 | DB01592 | 1,656 | 1,596 | [
"DDInter976",
"DDInter975"
] | Iron Dextran | Iron | Iron dextran is a dark brown, slightly viscous liquid complex of ferric hydroxide and dextran for intravenous or intramuscular use. Iron Dextran is used for the treatment of patients with documented iron deficiency in which oral administration is unsatisfactory or impossible. | A metallic element found in certain minerals, in nearly all soils, and in mineral waters. It is an essential constituent of hemoglobin, cytochrome, and other components of respiratory enzyme systems. Its chief functions are in the transport of oxygen to tissue (hemoglobin) and in cellular oxidation mechanisms. Depletio... | Moderate | 1 | [
[
[
1656,
24,
1596
]
],
[
[
1656,
63,
597
],
[
597,
24,
1596
]
],
[
[
1656,
25,
1575
],
[
1575,
64,
1596
]
],
[
[
1656,
63,
597
],
[
597,
... | [
[
[
"Iron Dextran",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iron"
]
],
[
[
"Iron Dextran",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chloramphenicol"
],
[... | Iron Dextran may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol and Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Iron
Iron Dextran may lead to a major life threatening interaction when taken with Dimercaprol and Dimercaprol ... |
DB00609 | DB00731 | 595 | 1,144 | [
"DDInter694",
"DDInter1269"
] | Ethionamide | Nateglinide | A second-line antitubercular agent that inhibits mycolic acid synthesis. It also may be used for treatment of leprosy. (From Smith and Reynard, Textbook of Pharmacology, 1992, p868) | Nateglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Nateglinide is an amino acid derivative that ... | Moderate | 1 | [
[
[
595,
24,
1144
]
],
[
[
595,
63,
168
],
[
168,
24,
1144
]
],
[
[
595,
21,
28787
],
[
28787,
60,
1144
]
],
[
[
595,
25,
1510
],
[
1510,
... | [
[
[
"Ethionamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nateglinide"
]
],
[
[
"Ethionamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
],
[... | Ethionamide may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide
Ethionamide (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Nateglinide (... |
DB00529 | DB08871 | 789 | 36 | [
"DDInter779",
"DDInter666"
] | Foscarnet | Eribulin | An antiviral agent used in the treatment of cytomegalovirus retinitis. Foscarnet also shows activity against human herpes viruses and HIV. | Eribulin is a microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Eribulin was isolated from the marine sponge Halichondria okadai. Eribulin is also being investigated for... | Moderate | 1 | [
[
[
789,
24,
36
]
],
[
[
789,
63,
1424
],
[
1424,
24,
36
]
],
[
[
789,
24,
820
],
[
820,
24,
36
]
],
[
[
789,
24,
28
],
[
28,
63,
... | [
[
[
"Foscarnet",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eribulin"
]
],
[
[
"Foscarnet",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quinine"
],
[
"Qu... | Foscarnet may cause a moderate interaction that could exacerbate diseases when taken with Quinine and Quinine may cause a moderate interaction that could exacerbate diseases when taken with Eribulin
Foscarnet may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may... |
DB00026 | DB00322 | 1,184 | 141 | [
"DDInter94",
"DDInter742"
] | Anakinra | Floxuridine | Anakinra is a recombinant human interleukin-1 (IL-1) receptor antagonist (IL-1Ra) composed of 153 amino acid residues. Unlike native human IL-1Ra, anakinra has an additional methionine residue at the amino terminus. This drug binds to the IL-1 receptor, competing with and inhibiting the activity of IL-1 alpha and beta.... | An antineoplastic antimetabolite that is metabolized to fluorouracil when administered by rapid injection. Floxuridine is available as a sterile, nonpyrogenic, lyophilized powder for reconstitution. When administered by slow, continuous, intra-arterial infusion, it is converted to floxuridine monophosphate. It has been... | Moderate | 1 | [
[
[
1184,
24,
141
]
],
[
[
1184,
24,
1083
],
[
1083,
40,
141
]
],
[
[
1184,
25,
1064
],
[
1064,
25,
141
]
],
[
[
1184,
24,
611
],
[
611,
... | [
[
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Floxuridine"
]
],
[
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trifluridine"
],
[
... | Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Trifluridine and Trifluridine (Compound) resembles Floxuridine (Compound)
Anakinra may lead to a major life threatening interaction when taken with Cladribine and Cladribine may lead to a major life threatening interaction when tak... |
DB00682 | DB01118 | 126 | 33 | [
"DDInter1951",
"DDInter76"
] | Warfarin | Amiodarone | Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be not... | Amiodarone is a benzofuran derivative, anti-arrhythmic drug used commonly in a variety of settings. Most known for its approved indication in life-threatening ventricular arrhythmias, it is also used off-label in the outpatient and inpatient setting for atrial fibrillation. Because of its ability to cause serious toxic... | Major | 2 | [
[
[
126,
25,
33
]
],
[
[
126,
24,
540
],
[
540,
1,
33
]
],
[
[
126,
6,
7950
],
[
7950,
45,
33
]
],
[
[
126,
63,
1152
],
[
1152,
24,
... | [
[
[
"Warfarin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Amiodarone"
]
],
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dronedarone"
],
[
"Dronedarone",... | Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Dronedarone and Dronedarone (Compound) resembles Amiodarone (Compound)
Warfarin (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Amiodarone (Compound)
Warfarin may cause a moderate interaction that could exacerbate dise... |
DB00443 | DB06718 | 251 | 1,687 | [
"DDInter195",
"DDInter1709"
] | Betamethasone | Stanozolol | Betamethasone is a long-acting corticosteroid with immunosuppressive and antiinflammatory properties. It can be used topically to manage inflammatory skin conditions such as eczema, and parenterally to manage several disease states including autoimmune disorders. Betamethasone has potent glucocorticoid activity and neg... | Stanozolol is a synthetic anabolic steroid with therapeutic uses in treating hereditary angioedema. Stanozolol is derived from testosterone, and has been abused by several high profile professional athletes. | Moderate | 1 | [
[
[
251,
24,
1687
]
],
[
[
251,
24,
1546
],
[
1546,
1,
1687
]
],
[
[
251,
24,
1561
],
[
1561,
40,
1687
]
],
[
[
251,
35,
155
],
[
155,
... | [
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Stanozolol"
]
],
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methyltestosterone"
... | Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Methyltestosterone and Methyltestosterone (Compound) resembles Stanozolol (Compound)
Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Testosterone and Testosterone (Compound) resemb... |
DB00765 | DB01105 | 1,266 | 222 | [
"DDInter1205",
"DDInter1665"
] | Metyrosine | Sibutramine | An inhibitor of the enzyme tyrosine 3-monooxygenase, and consequently of the synthesis of catecholamines. It is used to control the symptoms of excessive sympathetic stimulation in patients with pheochromocytoma. (Martindale, The Extra Pharmacopoeia, 30th ed) | Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity. It is a centrally acting stimulant chemically related to amphetamines thus it is classified as a Schedule IV controlled sub... | Moderate | 1 | [
[
[
1266,
24,
222
]
],
[
[
1266,
21,
29356
],
[
29356,
60,
222
]
],
[
[
1266,
63,
128
],
[
128,
24,
222
]
],
[
[
1266,
24,
549
],
[
549,
... | [
[
[
"Metyrosine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
]
],
[
[
"Metyrosine",
"{u} (Compound) causes {v} (Side Effect)",
"Salivary hypersecretion"
],
[
"Salivary hypersecretion",
... | Metyrosine (Compound) causes Salivary hypersecretion (Side Effect) and Salivary hypersecretion (Side Effect) is caused by Sibutramine (Compound)
Metyrosine may cause a moderate interaction that could exacerbate diseases when taken with Dexbrompheniramine and Dexbrompheniramine may cause a moderate interaction that coul... |
DB08895 | DB08899 | 976 | 129 | [
"DDInter1825",
"DDInter649"
] | Tofacitinib | Enzalutamide | Tofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that affect hematopoiesis and immune cell function. It is approved by the FDA for treatment of moderate to severe rheumatoid arthritis that responds inadequately to methotrexate or in those who are intolerant ... | Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line ... | Major | 2 | [
[
[
976,
25,
129
]
],
[
[
976,
25,
110
],
[
110,
62,
129
]
],
[
[
976,
63,
608
],
[
608,
23,
129
]
],
[
[
976,
64,
1510
],
[
1510,
2... | [
[
[
"Tofacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enzalutamide"
]
],
[
[
"Tofacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Polatuzumab vedotin"
],
[
"Polatuzumab ... | Tofacitinib may lead to a major life threatening interaction when taken with Polatuzumab vedotin and Polatuzumab vedotin may cause a minor interaction that can limit clinical effects when taken with Enzalutamide
Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine and Li... |
DB06176 | DB08865 | 1,342 | 1,593 | [
"DDInter1616",
"DDInter448"
] | Romidepsin | Crizotinib | Romidepsin is a selective inhibitor of histone deacetylase, approved in the US in 2009 for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy. | Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-as... | Major | 2 | [
[
[
1342,
25,
1593
]
],
[
[
1342,
63,
479
],
[
479,
23,
1593
]
],
[
[
1342,
24,
283
],
[
283,
62,
1593
]
],
[
[
1342,
62,
1247
],
[
1247,
... | [
[
[
"Romidepsin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Crizotinib"
]
],
[
[
"Romidepsin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Donepezil"
],
[
"Donepezil",... | Romidepsin may cause a moderate interaction that could exacerbate diseases when taken with Donepezil and Donepezil may cause a minor interaction that can limit clinical effects when taken with Crizotinib
Romidepsin may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedratinib... |
DB00214 | DB01129 | 1,028 | 379 | [
"DDInter1836",
"DDInter1559"
] | Torasemide | Rabeprazole | Torasemide is a high-ceiling loop diuretic. Structurally, it is a pyridine-sulfonylurea used as an antihypertensive agent. Torasemide was first approved for clinical use by the FDA in 1993. | Rabeprazole is an antiulcer drug in the class of proton pump inhibitors. It is a prodrug - in the acid environment of the parietal cells it turns into active sulphenamide form. Rabeprazole inhibits the H+, K+ATPase of the coating gastric cells and dose-dependent oppresses basal and stimulated gastric acid secretion. | Moderate | 1 | [
[
[
1028,
24,
379
]
],
[
[
1028,
24,
1215
],
[
1215,
40,
379
]
],
[
[
1028,
24,
660
],
[
660,
1,
379
]
],
[
[
1028,
63,
837
],
[
837,
... | [
[
[
"Torasemide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rabeprazole"
]
],
[
[
"Torasemide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lansoprazole"
],
[... | Torasemide may cause a moderate interaction that could exacerbate diseases when taken with Lansoprazole and Lansoprazole (Compound) resembles Rabeprazole (Compound)
Torasemide may cause a moderate interaction that could exacerbate diseases when taken with Esomeprazole and Esomeprazole (Compound) resembles Rabeprazole (... |
DB01211 | DB05294 | 609 | 1,069 | [
"DDInter393",
"DDInter1917"
] | Clarithromycin | Vandetanib | Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarith... | Vandetanib is an oral once-daily kinase inhibitor of tumour angiogenesis and tumour cell proliferation with the potential for use in a broad range of tumour types. On April 6 2011, vandetanib was approved by the FDA to treat nonresectable, locally advanced, or metastatic medullary thyroid cancer in adult patients. | Major | 2 | [
[
[
609,
25,
1069
]
],
[
[
609,
63,
1195
],
[
1195,
40,
1069
]
],
[
[
609,
6,
8374
],
[
8374,
45,
1069
]
],
[
[
609,
21,
29343
],
[
29343,... | [
[
[
"Clarithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vandetanib"
]
],
[
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Erlotinib"
],
[
"Erl... | Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Erlotinib and Erlotinib (Compound) resembles Vandetanib (Compound)
Clarithromycin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Vandetanib (Compound)
Clarithromycin (Compound) causes Blood creatinine increased ... |
DB00655 | DB00682 | 559 | 126 | [
"DDInter682",
"DDInter1951"
] | Estrone | Warfarin | Estrone, one of the major mammalian estrogens, is an aromatized C18 steroid with a 3-hydroxyl group and a 17-ketone. It is produced in vivo from androstenedione or from testosterone via estradiol. It is produced primarily in the ovaries, placenta, and in peripheral tissues (especially adipose tissue) through conversion... | Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be not... | Moderate | 1 | [
[
[
559,
24,
126
]
],
[
[
559,
6,
9842
],
[
9842,
45,
126
]
],
[
[
559,
7,
2384
],
[
2384,
46,
126
]
],
[
[
559,
24,
135
],
[
135,
6... | [
[
[
"Estrone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Warfarin"
]
],
[
[
"Estrone",
"{u} (Compound) binds {v} (Gene)",
"CYP1A1"
],
[
"CYP1A1",
"{u} (Gene) is bound by {v} (Compound)",
"... | Estrone (Compound) binds CYP1A1 (Gene) and CYP1A1 (Gene) is bound by Warfarin (Compound)
Estrone (Compound) upregulates CDK6 (Gene) and CDK6 (Gene) is upregulated by Warfarin (Compound)
Estrone may cause a moderate interaction that could exacerbate diseases when taken with Albiglutide and Albiglutide may cause a minor ... |
DB00008 | DB00495 | 491 | 139 | [
"DDInter1407",
"DDInter1961"
] | Peginterferon alfa-2a | Zidovudine | Peginterferon alfa-2a is a form of recombinant interferon used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most co... | A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain... | Moderate | 1 | [
[
[
491,
24,
139
]
],
[
[
491,
25,
1477
],
[
1477,
40,
139
]
],
[
[
491,
24,
231
],
[
231,
40,
139
]
],
[
[
491,
24,
309
],
[
309,
6... | [
[
[
"Peginterferon alfa-2a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zidovudine"
]
],
[
[
"Peginterferon alfa-2a",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Telbivudine"
],
... | Peginterferon alfa-2a may lead to a major life threatening interaction when taken with Telbivudine and Telbivudine (Compound) resembles Zidovudine (Compound)
Peginterferon alfa-2a may cause a moderate interaction that could exacerbate diseases when taken with Stavudine and Stavudine (Compound) resembles Zidovudine (Com... |
DB00443 | DB01390 | 251 | 1,117 | [
"DDInter195",
"DDInter1683"
] | Betamethasone | Sodium bicarbonate | Betamethasone is a long-acting corticosteroid with immunosuppressive and antiinflammatory properties. It can be used topically to manage inflammatory skin conditions such as eczema, and parenterally to manage several disease states including autoimmune disorders. Betamethasone has potent glucocorticoid activity and neg... | Sodium bicarbonate is a white, crystalline powder that is commonly used as a pH buffering agent, an electrolyte replenisher, systemic alkalizer and in topical cleansing solutions. | Minor | 0 | [
[
[
251,
23,
1117
]
],
[
[
251,
21,
29093
],
[
29093,
60,
1117
]
],
[
[
251,
1,
1220
],
[
1220,
23,
1117
]
],
[
[
251,
62,
1018
],
[
1018,... | [
[
[
"Betamethasone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sodium bicarbonate"
]
],
[
[
"Betamethasone",
"{u} (Compound) causes {v} (Side Effect)",
"Fatigue"
],
[
"Fatigue",
"{u} (Side Effect)... | Betamethasone (Compound) causes Fatigue (Side Effect) and Fatigue (Side Effect) is caused by Sodium bicarbonate (Compound)
Betamethasone (Compound) resembles Dexamethasone (Compound) and Dexamethasone may cause a minor interaction that can limit clinical effects when taken with Sodium bicarbonate
Betamethasone may caus... |
DB01105 | DB06706 | 222 | 468 | [
"DDInter1665",
"DDInter985"
] | Sibutramine | Isometheptene | Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity. It is a centrally acting stimulant chemically related to amphetamines thus it is classified as a Schedule IV controlled sub... | Isometheptene is a sympathomimetic drug that causes vasoconstriction. It is used for treating migraines and tension headaches. | Moderate | 1 | [
[
[
222,
24,
468
]
],
[
[
222,
63,
480
],
[
480,
24,
468
]
],
[
[
222,
64,
1100
],
[
1100,
24,
468
]
],
[
[
222,
25,
643
],
[
643,
2... | [
[
[
"Sibutramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isometheptene"
]
],
[
[
"Sibutramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Formoterol"
],
... | Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Isometheptene
Sibutramine may lead to a major life threatening interaction when taken with Venlafaxine and Venlafaxine may... |
DB00552 | DB11003 | 1,238 | 748 | [
"DDInter1425",
"DDInter100"
] | Pentostatin | Anthrax vaccine | A potent inhibitor of adenosine deaminase. The drug is effective in the treatment of many lymphoproliferative malignancies, particularly hairy-cell leukemia. It is also synergistic with some other antineoplastic agents and has immunosuppressive activity. | Anthrax vaccine is a vaccine used for the pre- or post-exposure prophylaxis of disease in those at high risk of, suspected or confirmed exposure to *Bacillus anthracis*. It is subcutaneously or intramuscularly administered. It is derived from cell-free filtrates of microaerophilic cultures of an avirulent, nonencapsula... | Moderate | 1 | [
[
[
1238,
24,
748
]
],
[
[
1238,
24,
896
],
[
896,
24,
748
]
],
[
[
1238,
25,
676
],
[
676,
63,
748
]
],
[
[
1238,
63,
970
],
[
970,
... | [
[
[
"Pentostatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anthrax vaccine"
]
],
[
[
"Pentostatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etoposide"
],
... | Pentostatin may cause a moderate interaction that could exacerbate diseases when taken with Etoposide and Etoposide may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine
Pentostatin may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib m... |
DB09154 | DB14509 | 1,475 | 1,399 | [
"DDInter1686",
"DDInter1081"
] | Sodium citrate | Lithium carbonate | Sodium citrate is the sodium salt of citric acid. It is white, crystalline powder or white, granular crystals, slightly deliquescent in moist air, freely soluble in water, practically insoluble in alcohol. Like citric acid, it has a sour taste. From the medical point of view, it is used as alkalinizing agent. It works ... | Lithium has been used to treat manic episodes since the 19th century. Though it is widely used, its mechanism of action is still unknown[FDA Label][A14585,A176642,A176651,L5843]. Lithium carbonate has a narrow therapeutic range and so careful monitoring is required to avoid adverse effects[FDA Label]. | Moderate | 1 | [
[
[
1475,
24,
1399
]
],
[
[
1475,
63,
964
],
[
964,
23,
1399
]
],
[
[
1475,
63,
1213
],
[
1213,
24,
1399
]
],
[
[
1475,
62,
1411
],
[
1411... | [
[
[
"Sodium citrate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lithium carbonate"
]
],
[
[
"Sodium citrate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxycycline"... | Sodium citrate may cause a moderate interaction that could exacerbate diseases when taken with Doxycycline and Doxycycline may cause a minor interaction that can limit clinical effects when taken with Lithium carbonate
Sodium citrate may cause a moderate interaction that could exacerbate diseases when taken with Dasati... |
DB00470 | DB01080 | 530 | 855 | [
"DDInter601",
"DDInter1933"
] | Dronabinol | Vigabatrin | Dronabinol (marketed as Marinol) is a synthetic form of delta-9-tetrahydrocannabinol (Δ⁹-THC), the primary psychoactive component of cannabis (marijuana). THC demonstrates its effects through weak partial agonist activity at Cannabinoid-1 (CB1R) and Cannabinoid-2 (CB2R) receptors, which results in the well-known effect... | Vigabatrin is an analog of gamma-aminobutyric acid ([GABA]), the main inhibitory neurotransmitter in the central nervous system, used in the treatment of refractory seizures and infantile spasms. It irreversibly inhibits the enzyme responsible for GABA metabolism, thereby increasing levels of circulating GABA. Although... | Moderate | 1 | [
[
[
530,
24,
855
]
],
[
[
530,
21,
28975
],
[
28975,
60,
855
]
],
[
[
530,
24,
407
],
[
407,
63,
855
]
],
[
[
530,
24,
401
],
[
401,
... | [
[
[
"Dronabinol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vigabatrin"
]
],
[
[
"Dronabinol",
"{u} (Compound) causes {v} (Side Effect)",
"Tension"
],
[
"Tension",
"{u} (Side Effect) is caused b... | Dronabinol (Compound) causes Tension (Side Effect) and Tension (Side Effect) is caused by Vigabatrin (Compound)
Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium may cause a moderate interaction that could exacerbate diseases when taken with Vigabatrin
Dronabinol... |
DB00549 | DB11978 | 522 | 124 | [
"DDInter1955",
"DDInter822"
] | Zafirlukast | Glasdegib | Zafirlukast is an oral leukotriene receptor antagonist (LTRA) for the maintenance treatment of asthma, often used in conjunction with an inhaled steroid and/or long-acting bronchodilator. It is available as a tablet and is usually dosed twice daily. Another leukotriene receptor antagonist is montelukast (Singulair), wh... | Glasdegib, also known as PF-04449913, is a small-molecule hedgehog signaling inhibitor selected under the group of benzimidazoles. In early research, benzimidazoles attracted large interest as they represented a class of inhibitors with low molecular weight, potent inhibitory activity, and lacking unstable functionalit... | Moderate | 1 | [
[
[
522,
24,
124
]
],
[
[
522,
24,
112
],
[
112,
23,
124
]
],
[
[
522,
24,
829
],
[
829,
63,
124
]
],
[
[
522,
24,
749
],
[
749,
24,... | [
[
[
"Zafirlukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glasdegib"
]
],
[
[
"Zafirlukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
... | Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Glasdegib
Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Ubrogepant and U... |
DB01176 | DB11186 | 537 | 1,609 | [
"DDInter453",
"DDInter1427"
] | Cyclizine | Pentoxyverine | A histamine H1 antagonist given by mouth or parenterally for the control of postoperative and drug-induced vomiting and in motion sickness. (From Martindale, The Extra Pharmacopoeia, 30th ed, p935) | Pentoxyverine, also referred to as carbetapentane, is a non-opioid central acting antitussive with antimuscarinic, anticonvulsant , and local anesthetic properties. It is an active ingredient in over-the-counter cough suppressants in combination with guaifenesin and H1-receptor antagonists . Pentoxyverine acts on sigma... | Moderate | 1 | [
[
[
537,
24,
1609
]
],
[
[
537,
63,
314
],
[
314,
24,
1609
]
],
[
[
537,
64,
306
],
[
306,
24,
1609
]
],
[
[
537,
24,
716
],
[
716,
... | [
[
[
"Cyclizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentoxyverine"
]
],
[
[
"Cyclizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nalbuphine"
],
[
... | Cyclizine may cause a moderate interaction that could exacerbate diseases when taken with Nalbuphine and Nalbuphine may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine
Cyclizine may lead to a major life threatening interaction when taken with Zonisamide and Zonisamide may cause... |
DB00999 | DB01234 | 504 | 1,220 | [
"DDInter883",
"DDInter513"
] | Hydrochlorothiazide | Dexamethasone | Hydrochlorothiazide is the most commonly prescribed thiazide diuretic. It is indicated to treat edema and hypertension.[A185138,L8447,L8450] Hydrochlorothiazide use is common but declining in favour of angiotensin converting enzyme inhibitors. Many combination products are available containing hydrochlorothiazide and a... | Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like [... | Moderate | 1 | [
[
[
504,
24,
1220
]
],
[
[
504,
63,
870
],
[
870,
1,
1220
]
],
[
[
504,
63,
175
],
[
175,
40,
1220
]
],
[
[
504,
18,
7710
],
[
7710,
... | [
[
[
"Hydrochlorothiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
]
],
[
[
"Hydrochlorothiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludro... | Hydrochlorothiazide may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludrocortisone (Compound) resembles Dexamethasone (Compound)
Hydrochlorothiazide may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone (Compo... |
DB15091 | DB15965 | 676 | 1,330 | [
"DDInter1901",
"DDInter1270"
] | Upadacitinib | Naxitamab | Upadacitinib is an oral Janus kinase (JAK)1-selective inhibitor and a disease-modifying antirheumatic drug (DMARD) used in the treatment of rheumatoid arthritis to slow down disease progression. Rheumatoid arthritis is a chronic autoimmune inflammatory disease affecting the peripheral joints. It is characterized by syn... | Naxitamab (humanized 3F8, hu3F8) is an IgG1 monoclonal antibody directed against the oncofetal differentiation antigen GD2 disialoganglioside.[L24454,A224604] Normally expressed during fetal development and in mature neurons, pain fibers, and skin cells, GD2 constitutes a highly efficient target in the treatment of neu... | Major | 2 | [
[
[
676,
25,
1330
]
],
[
[
676,
62,
1193
],
[
1193,
23,
1330
]
],
[
[
676,
64,
1532
],
[
1532,
24,
1330
]
],
[
[
676,
63,
597
],
[
597,
... | [
[
[
"Upadacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naxitamab"
]
],
[
[
"Upadacitinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc gluconate"
],
[
"Zinc ... | Upadacitinib may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Naxitamab
Upadacitinib may lead to a major life threatening interaction when taken with Ifosfamide and Ifosfamide may... |
DB00624 | DB12332 | 1,561 | 1,619 | [
"DDInter1776",
"DDInter1626"
] | Testosterone (topical) | Rucaparib | Testosterone is an androstanoid having 17beta-hydroxy and 3-oxo groups, together with unsaturation at C-4-C-5.. It has a role as an androgen, a human metabolite, a Daphnia magna metabolite and a mouse metabolite. It is a 17beta-hydroxy steroid, an androstanoid, a C19-steroid and a 3-oxo-Delta(4) steroid. | Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality. By targeting the ... | Moderate | 1 | [
[
[
1561,
24,
1619
]
],
[
[
1561,
63,
1419
],
[
1419,
24,
1619
]
],
[
[
1561,
24,
1213
],
[
1213,
24,
1619
]
],
[
[
1561,
40,
1438
],
[
14... | [
[
[
"Testosterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Testosterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Imatinib"
],
[
... | Testosterone may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Testosterone may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Testosterone... |
DB00661 | DB00757 | 122 | 1,166 | [
"DDInter1928",
"DDInter581"
] | Verapamil | Dolasetron | Verapamil is a phenylalkylamine calcium channel blocker used in the treatment of high blood pressure, heart arrhythmias, and angina, and was the first calcium channel antagonist to be introduced into therapy in the early 1960s. It is a member of the non-dihydropyridine class of calcium channel blockers, which includes ... | Dolasetron is an antinauseant and antiemetic agent indicated for the prevention of nausea and vomiting associated with moderately-emetogenic cancer chemotherapy and for the prevention of postoperative nausea and vomiting. Dolasetron is a highly specific and selective serotonin 5-HT3 receptor antagonist. This drug is no... | Major | 2 | [
[
[
122,
25,
1166
]
],
[
[
122,
6,
12523
],
[
12523,
45,
1166
]
],
[
[
122,
7,
6952
],
[
6952,
46,
1166
]
],
[
[
122,
21,
29081
],
[
29081... | [
[
[
"Verapamil",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dolasetron"
]
],
[
[
"Verapamil",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"Dolasetro... | Verapamil (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Dolasetron (Compound)
Verapamil (Compound) upregulates MCOLN1 (Gene) and MCOLN1 (Gene) is upregulated by Dolasetron (Compound)
Verapamil (Compound) causes Angioedema (Side Effect) and Angioedema (Side Effect) is caused by Dolasetron (Compound)
Verap... |
DB08827 | DB11730 | 990 | 351 | [
"DDInter1085",
"DDInter1588"
] | Lomitapide | Ribociclib | Lomitapide is a microsomal triglyceride transfer protein (MTP) inhibitor used in homozygous familial hypercholesterolemia (HoFH) patients. It is marketed under the name Juxtapid (R). | Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced p... | Major | 2 | [
[
[
990,
25,
351
]
],
[
[
990,
25,
283
],
[
283,
62,
351
]
],
[
[
990,
63,
310
],
[
310,
24,
351
]
],
[
[
990,
64,
597
],
[
597,
24,... | [
[
[
"Lomitapide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
]
],
[
[
"Lomitapide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fedratinib"
],
[
"Fedratinib",
"{u} m... | Lomitapide may lead to a major life threatening interaction when taken with Fedratinib and Fedratinib may cause a minor interaction that can limit clinical effects when taken with Ribociclib
Lomitapide may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel and Cabazitaxel may cause ... |
DB00280 | DB00981 | 494 | 1,528 | [
"DDInter575",
"DDInter1463"
] | Disopyramide | Physostigmine (ophthalmic) | A class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar to that of guanidine. It also possesses some anticholinergic and local anesthetic properties. | Physostigmine is a carbamate ester and an indole alkaloid. It has a role as a miotic, an EC 3.1.1.8 (cholinesterase) inhibitor and an antidote to curare poisoning. | Moderate | 1 | [
[
[
494,
24,
1528
]
],
[
[
494,
21,
28658
],
[
28658,
60,
1528
]
],
[
[
494,
24,
1511
],
[
1511,
63,
1528
]
],
[
[
494,
24,
543
],
[
543,
... | [
[
[
"Disopyramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Physostigmine"
]
],
[
[
"Disopyramide",
"{u} (Compound) causes {v} (Side Effect)",
"Vomiting"
],
[
"Vomiting",
"{u} (Side Effect) is... | Disopyramide may cause a moderate interaction that could exacerbate diseases when taken with Physostigmine
Disopyramide (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Physostigmine (Compound)
Disopyramide may cause a moderate interaction that could exacerbate diseases when taken with M... |
DB11642 | DB12130 | 938 | 1,017 | [
"DDInter1480",
"DDInter1094"
] | Pitolisant | Lorlatinib | Pitolisant is a selective antagonist or inverse agonist of the histamine H3 receptor used to treat type 1 or 2 narcolepsy. Narcolepsy is a chronic neurological disorder that affects 1 in 2,000 individuals and is characterized by excessive daytime sleepiness, abnormal REM sleep manifestations, sleep paralysis and hypnag... | Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-... | Major | 2 | [
[
[
938,
25,
1017
]
],
[
[
938,
63,
175
],
[
175,
24,
1017
]
],
[
[
938,
24,
1421
],
[
1421,
63,
1017
]
],
[
[
938,
64,
11
],
[
11,
... | [
[
[
"Pitolisant",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lorlatinib"
]
],
[
[
"Pitolisant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triamcinolone"
],
[
"Triamci... | Pitolisant may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Pitolisant may cause a moderate interaction that could exacerbate diseases when taken with Betrixaban and ... |
DB09034 | DB12141 | 1,313 | 971 | [
"DDInter1733",
"DDInter817"
] | Suvorexant | Gilteritinib | Suvorexant is a selective dual antagonist of orexin receptors OX1R and OX2R that promotes sleep by reducing wakefulness and arousal. It has been approved for the treatment of insomnia. | Gilteritinib, also known as ASP2215, is a small molecule part of the FLT3 tyrosine kinase inhibitors that presented a greater selectivity and potency when compared with other agents from this group. It is a pyrazinecarboxamide derivative that showed high selectivity to FLT3 preventing the c-Kit -driven myelosuppression... | Moderate | 1 | [
[
[
1313,
24,
971
]
],
[
[
1313,
23,
1135
],
[
1135,
23,
971
]
],
[
[
1313,
63,
820
],
[
820,
24,
971
]
],
[
[
1313,
25,
283
],
[
283,
... | [
[
[
"Suvorexant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
]
],
[
[
"Suvorexant",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Naloxegol"
],
[
... | Suvorexant may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Gilteritinib
Suvorexant may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazi... |
DB00242 | DB11791 | 1,064 | 785 | [
"DDInter392",
"DDInter287"
] | Cladribine | Capmatinib | An antineoplastic agent used in the treatment of lymphoproliferative diseases including hairy-cell leukemia. | Capmatinib is a small molecule kinase inhibitor targeted against c-Met (a.k.a. hepatocyte growth factor receptor [HGFR]), a receptor tyrosine kinase that, in healthy humans, activates signaling cascades involved in organ regeneration and tissue repair. Aberrant c-Met activation - via mutations, amplification, and/or ov... | Moderate | 1 | [
[
[
1064,
24,
785
]
],
[
[
1064,
25,
310
],
[
310,
24,
785
]
],
[
[
1064,
63,
912
],
[
912,
24,
785
]
],
[
[
1064,
25,
738
],
[
738,
... | [
[
[
"Cladribine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Capmatinib"
]
],
[
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cabazitaxel"
],
[
"Cabazitax... | Cladribine may lead to a major life threatening interaction when taken with Cabazitaxel and Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Capmatinib
Cladribine may cause a moderate interaction that could exacerbate diseases when taken with Interferon beta-1a and Interferon ... |
DB00407 | DB00574 | 202 | 121 | [
"DDInter115",
"DDInter717"
] | Ardeparin | Fenfluramine | Ardeparin, marketed under the US trade name Normiflo, is a low molecular weight heparin (LMWH) anticoagulant used for the prevention of postoperative venous thrombosis. Ardeparin is derived via peroxide degradation of heparin extracted from porcine intestinal mucosa. Its molecular weight ranges from 2000 to 15,000 with... | Dravet syndrome is a pediatric encephalopathy that typically manifests within the first year of life following exposure to elevated temperatures. It is characterized by recurrent pharmacoresistant seizures, which increase in frequency and severity with disease progression. Concomitantly with these seizures, patients ty... | Moderate | 1 | [
[
[
202,
24,
121
]
],
[
[
202,
64,
366
],
[
366,
24,
121
]
],
[
[
202,
25,
292
],
[
292,
63,
121
]
],
[
[
202,
37,
1274
],
[
1274,
6... | [
[
[
"Ardeparin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fenfluramine"
]
],
[
[
"Ardeparin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Eptifibatide"
],
[
"Eptifiba... | Ardeparin may lead to a major life threatening interaction when taken with Eptifibatide and Eptifibatide may cause a moderate interaction that could exacerbate diseases when taken with Fenfluramine
Ardeparin may lead to a major life threatening interaction when taken with Regorafenib and Regorafenib may cause a moderat... |
DB00690 | DB11901 | 1,216 | 913 | [
"DDInter762",
"DDInter107"
] | Flurazepam | Apalutamide | A benzodiazepine derivative used mainly as a hypnotic. | Apalutamide is a potent androgen receptor (AR) antagonist that selectively binds to the ligand-binding domain of AR and blocks AR nuclear translocation or binding to androgen response elements . It has been used in trials studying the treatment of Prostate Cancer, Hepatic Impairment, Prostatic Neoplasms, Castration-Res... | Moderate | 1 | [
[
[
1216,
24,
913
]
],
[
[
1216,
63,
608
],
[
608,
23,
913
]
],
[
[
1216,
40,
1237
],
[
1237,
24,
913
]
],
[
[
1216,
24,
609
],
[
609,
... | [
[
[
"Flurazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
]
],
[
[
"Flurazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lidocaine"
],
[
... | Flurazepam may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Apalutamide
Flurazepam (Compound) resembles Clomipramine (Compound) and Clomipramine may cause a moderate interaction that coul... |
DB12332 | DB15035 | 1,619 | 503 | [
"DDInter1626",
"DDInter1959"
] | Rucaparib | Zanubrutinib | Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality. By targeting the ... | Zanubrutinib is a novel Bruton's tyrosine kinase (BTK) inhibitor used for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. Mantle cell lymphoma is an aggressive mature B-cell non-Hodgkin lymphoma associated with early relapse, poor clinical outcomes, and long... | Moderate | 1 | [
[
[
1619,
24,
503
]
],
[
[
1619,
25,
982
],
[
982,
24,
503
]
],
[
[
1619,
64,
868
],
[
868,
24,
503
]
],
[
[
1619,
62,
222
],
[
222,
... | [
[
[
"Rucaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zanubrutinib"
]
],
[
[
"Rucaparib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivosidenib"
],
[
"Ivosidenib... | Rucaparib may lead to a major life threatening interaction when taken with Ivosidenib and Ivosidenib may cause a moderate interaction that could exacerbate diseases when taken with Zanubrutinib
Rucaparib may lead to a major life threatening interaction when taken with Vemurafenib and Vemurafenib may cause a moderate in... |
DB01390 | DB08864 | 1,117 | 786 | [
"DDInter1683",
"DDInter1595"
] | Sodium bicarbonate | Rilpivirine | Sodium bicarbonate is a white, crystalline powder that is commonly used as a pH buffering agent, an electrolyte replenisher, systemic alkalizer and in topical cleansing solutions. | Rilpivirine is non-nucleoside reverse transcriptase inhibitor (NNRTI) which is used for the treatment of HIV-1 infections in treatment-naive patients. It is a diarylpyrimidine derivative. The internal conformational flexibility of rilpivirine and the plasticity of it interacting binding site gives it a very high potenc... | Moderate | 1 | [
[
[
1117,
24,
786
]
],
[
[
1117,
21,
29343
],
[
29343,
60,
786
]
],
[
[
1117,
24,
594
],
[
594,
24,
786
]
],
[
[
1117,
62,
663
],
[
663,
... | [
[
[
"Sodium bicarbonate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilpivirine"
]
],
[
[
"Sodium bicarbonate",
"{u} (Compound) causes {v} (Side Effect)",
"Blood creatinine increased"
],
[
"Blood crea... | Sodium bicarbonate (Compound) causes Blood creatinine increased (Side Effect) and Blood creatinine increased (Side Effect) is caused by Rilpivirine (Compound)
Sodium bicarbonate may cause a moderate interaction that could exacerbate diseases when taken with Bosutinib and Bosutinib may cause a moderate interaction that ... |
DB06605 | DB11312 | 1,409 | 298 | [
"DDInter108",
"DDInter1542"
] | Apixaban | Protein C | Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic diseases[Label,A6897]. It is marketed under the name Eliquis[Label,L6043]. Apixaban was approved by the FD... | Protein C is an endogenously occurring plasma protein that plays a key role within the coagulation cascade. Protein C is a zymogen, or enzyme precursor, of a vitamin K-dependent anticoagulant glycoprotein (serine protease) that is synthesized in the liver. It is converted by the thrombin/thrombomodulin-complex on the e... | Moderate | 1 | [
[
[
1409,
24,
298
]
],
[
[
1409,
25,
707
],
[
707,
24,
298
]
],
[
[
1409,
24,
321
],
[
321,
63,
298
]
],
[
[
1409,
64,
500
],
[
500,
... | [
[
[
"Apixaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Protein C"
]
],
[
[
"Apixaban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Danaparoid"
],
[
"Danaparoid",
... | Apixaban may lead to a major life threatening interaction when taken with Danaparoid and Danaparoid may cause a moderate interaction that could exacerbate diseases when taken with Protein C
Apixaban may cause a moderate interaction that could exacerbate diseases when taken with Selumetinib and Selumetinib may cause a m... |
DB00557 | DB01181 | 252 | 1,532 | [
"DDInter895",
"DDInter906"
] | Hydroxyzine | Ifosfamide | Hydroxyzine is a first-generation histamine H<sub>1</sub>-receptor antagonist of the dephenylmethane and piperazine classes that exhibits sedative, anxiolytic, and antiemetic properties.[A1257,A187589] It was first developed in 1955, and has since remained a relatively common treatment for allergic conditions such as p... | Ifosfamide is a chemotherapeutic agent chemically related to the nitrogen mustards and a synthetic analog of cyclophosphamide. It is active as an alkylating agent and an immunosuppressive agent. | Moderate | 1 | [
[
[
252,
24,
1532
]
],
[
[
252,
21,
28893
],
[
28893,
60,
1532
]
],
[
[
252,
63,
1648
],
[
1648,
24,
1532
]
],
[
[
252,
25,
351
],
[
351,
... | [
[
[
"Hydroxyzine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ifosfamide"
]
],
[
[
"Hydroxyzine",
"{u} (Compound) causes {v} (Side Effect)",
"Hallucination"
],
[
"Hallucination",
"{u} (Side Effec... | Hydroxyzine (Compound) causes Hallucination (Side Effect) and Hallucination (Side Effect) is caused by Ifosfamide (Compound)
Hydroxyzine may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken ... |
DB05273 | DB08885 | 507 | 363 | [
"DDInter1638",
"DDInter33"
] | Samarium (153Sm) lexidronam | Aflibercept | Samarium Sm 153 lexidronam is a radioactive medication used to treat pain caused by cancer that has spread to the bone. It is a radiopharmaceutical. Radiopharmaceuticals are radioactive agents that may be used to diagnose some diseases by studying the function of the body's organs or to treat certain diseases.Samarium ... | Aflibercept is a recombinant protein composed of the binding domains of two human vascular endothelial growth factor (VEGF) receptors, VEGFR1 and VEGFR2, fused with the Fc region of human immunoglobulin gamma 1 (IgG1). Structurally, Aflibercept is a dimeric glycoprotein with a protein molecular weight of 96.9 kilo Dalt... | Major | 2 | [
[
[
507,
25,
363
]
],
[
[
507,
25,
384
],
[
384,
63,
363
]
],
[
[
507,
24,
270
],
[
270,
63,
363
]
],
[
[
507,
64,
869
],
[
869,
24,... | [
[
[
"Samarium (153Sm) lexidronam",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Aflibercept"
]
],
[
[
"Samarium (153Sm) lexidronam",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Idelalisib"
],
... | Samarium (153Sm) lexidronam may lead to a major life threatening interaction when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Aflibercept
Samarium (153Sm) lexidronam may cause a moderate interaction that could exacerbate diseases when taken with O... |
DB00263 | DB09564 | 1,029 | 1,296 | [
"DDInter1727",
"DDInter930"
] | Sulfisoxazole | Insulin degludec | A short-acting sulfonamide antibacterial with activity against a wide range of gram- negative and gram-positive organisms. | Insulin degludec is an ultra-long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes.[A18561,A18562,A18563,A18564,A174934] Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide horm... | Moderate | 1 | [
[
[
1029,
24,
1296
]
],
[
[
1029,
24,
1411
],
[
1411,
24,
1296
]
],
[
[
1029,
63,
305
],
[
305,
24,
1296
]
],
[
[
1029,
40,
698
],
[
698,
... | [
[
[
"Sulfisoxazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
]
],
[
[
"Sulfisoxazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
... | Sulfisoxazole may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec
Sulfisoxazole may cause a moderate interaction that could exacerbate diseases when taken with Asparag... |
DB00422 | DB00983 | 895 | 480 | [
"DDInter1189",
"DDInter776"
] | Methylphenidate | Formoterol | Methylphenidate is a central nervous system stimulant used most commonly in the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) and for narcolepsy. Also known as the marketed products Ritalin, Concerta, or Biphentin, methylphenidate is used with other treatment modalities (psychological, educational, cogni... | Formoterol is an inhaled beta<sub>2</sub>-agonist used in the management of COPD and asthma that was first approved for use in the United States in 2001. It acts on bronchial smooth muscle to dilate and relax airways, and is administered as a racemic mixture of its active (R;R)- and inactive (S;S)-enantiomers. A major ... | Moderate | 1 | [
[
[
895,
24,
480
]
],
[
[
895,
24,
1148
],
[
1148,
63,
480
]
],
[
[
895,
6,
12523
],
[
12523,
45,
480
]
],
[
[
895,
21,
28963
],
[
28963,
... | [
[
[
"Methylphenidate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Formoterol"
]
],
[
[
"Methylphenidate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoprenaline"
... | Methylphenidate may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline and Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Formoterol
Methylphenidate (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Formoterol (Compound)
Meth... |
DB00719 | DB01219 | 1,219 | 716 | [
"DDInter149",
"DDInter473"
] | Azatadine | Dantrolene | Antihistamines such as azatadine appear to compete with histamine for histamine H1- receptor sites on effector cells. The antihistamines antagonize those pharmacological effects of histamine which are mediated through activation of H1- receptor sites and thereby reduce the intensity of allergic reactions and tissue inj... | Chemically, dantrolene is a hydantoin derivative, but does not exhibit antiepileptic activity like other hydantoin derivates such as phenytoin. | Moderate | 1 | [
[
[
1219,
24,
716
]
],
[
[
1219,
6,
8374
],
[
8374,
45,
716
]
],
[
[
1219,
24,
1609
],
[
1609,
63,
716
]
],
[
[
1219,
24,
100
],
[
100,
... | [
[
[
"Azatadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dantrolene"
]
],
[
[
"Azatadine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Azatadine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Dantrolene (Compound)
Azatadine may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine and Pentoxyverine may cause a moderate interaction that could exacerbate diseases when taken with Dantrolene
Azatadine may ... |
DB00361 | DB09118 | 134 | 1,580 | [
"DDInter1939",
"DDInter1711"
] | Vinorelbine | Stiripentol | Vinorelbine is an anti-mitotic chemotherapy drug that is used in the treatment of several types of malignancies, including breast cancer and non-small cell lung cancer (NSCLC). It was initially approved in the USA in 1990's for the treatment of NSCLC. It is a third-generation vinca alkaloid. The introduction of third-g... | Stiripentol is an antiepileptic agent that is an aromatic allylic alcohol drug, which makes it structurally unique from other antiepileptic drugs.[A19740, A250825] The clinical development and marketing of stiripentol were first delayed due to the drug's potent inhibitory effects on hepatic cytochrome P450 (CYP) enzyme... | Moderate | 1 | [
[
[
134,
24,
1580
]
],
[
[
134,
24,
283
],
[
283,
63,
1580
]
],
[
[
134,
63,
168
],
[
168,
24,
1580
]
],
[
[
134,
24,
1532
],
[
1532,
... | [
[
[
"Vinorelbine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Stiripentol"
]
],
[
[
"Vinorelbine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
],
[... | Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedratinib may cause a moderate interaction that could exacerbate diseases when taken with Stiripentol
Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bor... |
DB00067 | DB01041 | 317 | 770 | [
"DDInter1921",
"DDInter1789"
] | Vasopressin | Thalidomide | Vasopressin (arginine-vasopressin or antidiuretic hormone) is a nonapeptide primarily produced in the hypothalamus that exhibits diverse physiological functions related to diuresis, hemodynamic modulation, and behaviour.[A110, A111, A112, A113, A228008] Vasopressin is very similar to oxytocin, differing in the third an... | A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating ... | Moderate | 1 | [
[
[
317,
24,
770
]
],
[
[
317,
24,
609
],
[
609,
63,
770
]
],
[
[
317,
24,
1557
],
[
1557,
24,
770
]
],
[
[
317,
25,
982
],
[
982,
6... | [
[
[
"Vasopressin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
]
],
[
[
"Vasopressin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
],
... | Vasopressin may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide
Vasopressin may cause a moderate interaction that could exacerbate diseases when taken with Astemizole... |
DB00959 | DB04834 | 1,486 | 276 | [
"DDInter1191",
"DDInter1571"
] | Methylprednisolone | Rapacuronium | Methylprednisolone is a [prednisolone] derivative glucocorticoid with higher potency than [prednisone]. It was first described in the literature in the late 1950s.[A188811,A188814] Methylprednisolone was granted FDA approval on 24 October 1957. In the outbreak of COVID-19, low dose methylprednisolone-based therapy was ... | Rapacuronium was withdrawn in 2001 in many countries due to risk of fatal bronchospasm. | Moderate | 1 | [
[
[
1486,
24,
276
]
],
[
[
1486,
63,
1031
],
[
1031,
24,
276
]
],
[
[
1486,
40,
251
],
[
251,
24,
276
]
],
[
[
1486,
1,
175
],
[
175,
... | [
[
[
"Methylprednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rapacuronium"
]
],
[
[
"Methylprednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Theophyll... | Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Theophylline and Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Rapacuronium
Methylprednisolone (Compound) resembles Betamethasone (Compound) and Betamethasone may cause a mod... |
DB01203 | DB06292 | 699 | 549 | [
"DDInter1255",
"DDInter474"
] | Nadolol | Dapagliflozin | Nadolol is a nonselective beta adrenal receptor blocker that is used to lower blood pressure.[L7922,L7925] Nonselective beta adrenal receptor blockers may no longer be first line in the treatment of hypertension as newer generations of beta adrenal receptor blockers have higher selectivity and offer better rates of adv... | Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor, and it was the first SLGT2 inhibitor to be approved. indicated for managing diabetes mellitus type 2. When combined with diet and exercise in adults, dapagliflozin helps to improve glycemic control by inhibiting glucose reabsorption in the proximal tu... | Moderate | 1 | [
[
[
699,
24,
549
]
],
[
[
699,
24,
1344
],
[
1344,
40,
549
]
],
[
[
699,
6,
4973
],
[
4973,
45,
549
]
],
[
[
699,
21,
28882
],
[
28882,
... | [
[
[
"Nadolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapagliflozin"
]
],
[
[
"Nadolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canagliflozin"
],
[
... | Nadolol may cause a moderate interaction that could exacerbate diseases when taken with Canagliflozin and Canagliflozin (Compound) resembles Dapagliflozin (Compound)
Nadolol (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Dapagliflozin (Compound)
Nadolol (Compound) causes Body temperature increased (Side Eff... |
DB01097 | DB15822 | 1,377 | 69 | [
"DDInter1033",
"DDInter1504"
] | Leflunomide | Pralsetinib | Leflunomide is a pyrimidine synthesis inhibitor belonging to the DMARD (disease-modifying antirheumatic drug) class of drugs, which are chemically and pharmacologically very heterogeneous. Leflunomide was approved by FDA and in many other countries (e.g., Canada, Europe) in 1999. | Pralsetinib, similar to the previously approved [selpercatinib], is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A219751, L15986] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers, including non-small... | Major | 2 | [
[
[
1377,
25,
69
]
],
[
[
1377,
25,
283
],
[
283,
24,
69
]
],
[
[
1377,
64,
1648
],
[
1648,
24,
69
]
],
[
[
1377,
63,
597
],
[
597,
... | [
[
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pralsetinib"
]
],
[
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fedratinib"
],
[
"Fedratinib",
"{u... | Leflunomide may lead to a major life threatening interaction when taken with Fedratinib and Fedratinib may cause a moderate interaction that could exacerbate diseases when taken with Pralsetinib
Leflunomide may lead to a major life threatening interaction when taken with Aldesleukin and Aldesleukin may cause a moderate... |
DB00060 | DB01299 | 912 | 698 | [
"DDInter947",
"DDInter1722"
] | Interferon beta-1a | Sulfadoxine | Human interferon beta (166 residues), glycosylated, MW=22.5kD. It is produced by mammalian cells (Chinese Hamster Ovary cells) into which the human interferon beta gene has been introduced. The amino acid sequence is identical to that of natural human interferon beta. | A long acting sulfonamide that is used, usually in combination with other drugs, for respiratory, urinary tract, and malarial infections. | Moderate | 1 | [
[
[
912,
24,
698
]
],
[
[
912,
24,
1247
],
[
1247,
40,
698
]
],
[
[
912,
24,
161
],
[
161,
1,
698
]
],
[
[
912,
63,
1560
],
[
1560,
... | [
[
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfadoxine"
]
],
[
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sulfametho... | Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Sulfamethoxazole and Sulfamethoxazole (Compound) resembles Sulfadoxine (Compound)
Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Sulfadiazine and Sulfadiazine (Compound)... |
DB06674 | DB12001 | 908 | 564 | [
"DDInter837",
"DDInter7"
] | Golimumab | Abemaciclib | Golimumab is a human IgG1қ monoclonal antibody derived from immunizing genetically engineered mice with human TNFα. Golimumab binds and inhibits soluble and transmembrane human TNFα. Increased TNFα is associated with chronic inflammation. Thus golimumab is indicated for use in adults (i) as an adjunct to methotrexate t... | Abemaciclib is an antitumor agent and dual inhibitor of cyclin-dependent kinases 4 (CDK4) and 6 (CDK6) that are involved in the cell cycle and promotion of cancer cell growth in case of unregulated activity. On September 28, 2017, FDA granted approval of abemaciclib treatment under the market name Verzenio for the trea... | Major | 2 | [
[
[
908,
25,
564
]
],
[
[
908,
24,
748
],
[
748,
24,
564
]
],
[
[
908,
63,
58
],
[
58,
24,
564
]
],
[
[
908,
64,
259
],
[
259,
24,
... | [
[
[
"Golimumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Abemaciclib"
]
],
[
[
"Golimumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anthrax vaccine"
],
[
"Anthra... | Golimumab may cause a moderate interaction that could exacerbate diseases when taken with Anthrax vaccine and Anthrax vaccine may cause a moderate interaction that could exacerbate diseases when taken with Abemaciclib
Golimumab may cause a moderate interaction that could exacerbate diseases when taken with Alefacept an... |
DB01100 | DB01114 | 1,568 | 272 | [
"DDInter1470",
"DDInter362"
] | Pimozide | Chlorpheniramine | A diphenylbutylpiperidine that is effective as an antipsychotic agent and as an alternative to haloperidol for the suppression of vocal and motor tics in patients with Tourette syndrome. Although the precise mechanism of action is unknown, blockade of postsynaptic dopamine receptors has been postulated. (From AMA Drug ... | A histamine H1 antagonist used in allergic reactions, hay fever, rhinitis, urticaria, and asthma. It has also been used in veterinary applications. One of the most widely used of the classical antihistaminics, it generally causes less drowsiness and sedation than promethazine. | Moderate | 1 | [
[
[
1568,
24,
272
]
],
[
[
1568,
24,
849
],
[
849,
63,
272
]
],
[
[
1568,
63,
128
],
[
128,
24,
272
]
],
[
[
1568,
24,
28
],
[
28,
1... | [
[
[
"Pimozide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpheniramine"
]
],
[
[
"Pimozide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
],
[
... | Pimozide may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine
Pimozide may cause a moderate interaction that could exacerbate diseases when taken with Dexbrompheniramine ... |
DB04835 | DB08875 | 1,655 | 1,618 | [
"DDInter1125",
"DDInter262"
] | Maraviroc | Cabozantinib | Maraviroc (brand-named Selzentry, or Celsentri outside the U.S.) is a chemokine receptor antagonist drug developed by the drug company Pfizer that is designed to act against HIV by interfering with the interaction between HIV and CCR5. It was originally labelled as UK-427857 during development but was assigned the Mara... | Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced r... | Moderate | 1 | [
[
[
1655,
24,
1618
]
],
[
[
1655,
63,
723
],
[
723,
24,
1618
]
],
[
[
1655,
25,
384
],
[
384,
63,
1618
]
],
[
[
1655,
24,
1040
],
[
1040,
... | [
[
[
"Maraviroc",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabozantinib"
]
],
[
[
"Maraviroc",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
],
[
... | Maraviroc may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Cabozantinib
Maraviroc may lead to a major life threatening interaction when taken with Idelalisib and Idelalisib may cause ... |
DB06674 | DB15699 | 908 | 652 | [
"DDInter837",
"DDInter232"
] | Golimumab | Brexucabtagene autoleucel | Golimumab is a human IgG1қ monoclonal antibody derived from immunizing genetically engineered mice with human TNFα. Golimumab binds and inhibits soluble and transmembrane human TNFα. Increased TNFα is associated with chronic inflammation. Thus golimumab is indicated for use in adults (i) as an adjunct to methotrexate t... | Mantle cell lymphoma is a heterogeneous sub-category of non-Hodgkin's lymphoma that can be classified as either an aggressive nodal or an indolent leukemic non-nodal variant. Despite the introduction of Bruton's tyrosine kinase (BTK) inhibitors such as [ibrutinib] and [acalabrutinib], the prognosis for MCL patients rem... | Major | 2 | [
[
[
908,
25,
652
]
],
[
[
908,
64,
259
],
[
259,
24,
652
]
],
[
[
908,
24,
1430
],
[
1430,
24,
652
]
],
[
[
908,
25,
270
],
[
270,
2... | [
[
[
"Golimumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Brexucabtagene autoleucel"
]
],
[
[
"Golimumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rilonacept"
],
[
"Rilonacept",... | Golimumab may lead to a major life threatening interaction when taken with Rilonacept and Rilonacept may cause a moderate interaction that could exacerbate diseases when taken with Brexucabtagene autoleucel
Golimumab may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T and Sipule... |
DB00640 | DB01218 | 1,585 | 1,493 | [
"DDInter31",
"DDInter852"
] | Adenosine | Halofantrine | The structure of adenosine was first described in 1931, though the vasodilating effects were not described in literature until the 1940s. Adenosine is indicated as an adjunct to thallium-201 in myocardial perfusion scintigraphy, though it is rarely used in this indication, having largely been replaced by [dipyridamole]... | Halofantrine is an antimalarial. It belongs to the phenanthrene class of compounds that includes quinine and lumefantrine. It appears to inhibit polymerisation of heme molecules (by the parasite enzyme "heme polymerase"), resulting in the parasite being poisoned by its own waste. Halofantrine has been shown to preferen... | Major | 2 | [
[
[
1585,
25,
1493
]
],
[
[
1585,
18,
2183
],
[
2183,
57,
1493
]
],
[
[
1585,
21,
28763
],
[
28763,
60,
1493
]
],
[
[
1585,
24,
688
],
[
6... | [
[
[
"Adenosine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Halofantrine"
]
],
[
[
"Adenosine",
"{u} (Compound) downregulates {v} (Gene)",
"CDC20"
],
[
"CDC20",
"{u} (Gene) is downregulated by {v} (Compound)",
... | Adenosine (Compound) downregulates CDC20 (Gene) and CDC20 (Gene) is downregulated by Halofantrine (Compound)
Adenosine (Compound) causes Chest pain (Side Effect) and Chest pain (Side Effect) is caused by Halofantrine (Compound)
Adenosine may cause a moderate interaction that could exacerbate diseases when taken with Sa... |
DB00332 | DB01591 | 1,089 | 667 | [
"DDInter970",
"DDInter1696"
] | Ipratropium | Solifenacin | Ipratropium is a quaternary ammonium derivative of [atropine] that acts as an anticholinergic agent. It is commonly administered through inhalation which allows producing a local effect without presenting a significant systemic absorption. Ipratropium as a therapeutic agent was developed by Boehringer Ingelheim and its... | Solifenacin is a competitive muscarinic receptor antagonist indicated to treat an overactive bladder with urinary incontinence, urgency, and frequency. It has a long duration of action as it is usually taken once daily. Solifenacin was granted FDA approval on 19 November 2004. | Moderate | 1 | [
[
[
1089,
24,
667
]
],
[
[
1089,
6,
8894
],
[
8894,
45,
667
]
],
[
[
1089,
21,
28743
],
[
28743,
60,
667
]
],
[
[
1089,
24,
830
],
[
830,
... | [
[
[
"Ipratropium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Solifenacin"
]
],
[
[
"Ipratropium",
"{u} (Compound) binds {v} (Gene)",
"CHRM5"
],
[
"CHRM5",
"{u} (Gene) is bound by {v} (Compound)"... | Ipratropium (Compound) binds CHRM5 (Gene) and CHRM5 (Gene) is bound by Solifenacin (Compound)
Ipratropium (Compound) causes Atrial fibrillation (Side Effect) and Atrial fibrillation (Side Effect) is caused by Solifenacin (Compound)
Ipratropium may cause a moderate interaction that could exacerbate diseases when taken w... |
DB00023 | DB00033 | 305 | 342 | [
"DDInter127",
"DDInter949"
] | Asparaginase Escherichia coli | Interferon gamma-1b | Asparaginase derived from _Escherichia coli_ (L-asparagine amidohydrolase, EC 3.5.1.1) is an enzyme responsible for the metabolism of L-asparagine, by catalyzing L-asparagine into L-aspartic acid and ammonia. It also facilitates the production of oxaloacetate which is needed for general cellular metabolism. Asparaginas... | Human Interferon gamma-1b (140 residues), produced from E. coli. Production of Actimmune is achieved by fermentation of a genetically engineered Escherichia coli bacterium containing the DNA which encodes for the human protein. Purification of the product is achieved by conventional column chromatography. The sequence ... | Moderate | 1 | [
[
[
305,
24,
342
]
],
[
[
305,
24,
912
],
[
912,
63,
342
]
],
[
[
305,
63,
1257
],
[
1257,
24,
342
]
],
[
[
305,
25,
1259
],
[
1259,
... | [
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Interferon gamma-1b"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when take... | Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Interferon beta-1a and Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Interferon gamma-1b
Asparaginase Escherichia coli may cause a moderate interaction that ... |
DB00342 | DB06636 | 1,181 | 1,623 | [
"DDInter1770",
"DDInter980"
] | Terfenadine | Isavuconazonium | In the U.S., Terfenadine was superseded by fexofenadine in the 1990s due to the risk of cardiac arrhythmia caused by QT interval prolongation. | Isavuconazonium is a second-generation triazole antifungal approved on March 6, 2015 by the FDA and July 2015 by the EMA for the treatment of adults with invasive aspergillosis and invasive mucormycosis, marketed by Astellas under the brand Cresemba. It is the prodrug form of isavuconazole, the active moiety, and it is... | Moderate | 1 | [
[
[
1181,
24,
1623
]
],
[
[
1181,
24,
1419
],
[
1419,
24,
1623
]
],
[
[
1181,
25,
1487
],
[
1487,
24,
1623
]
],
[
[
1181,
25,
1593
],
[
15... | [
[
[
"Terfenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isavuconazonium"
]
],
[
[
"Terfenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Imatinib"
],
... | Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Isavuconazonium
Terfenadine may lead to a major life threatening interaction when taken with Hydroxychloroquine and Hydroxychl... |
DB01403 | DB09564 | 9 | 1,296 | [
"DDInter1175",
"DDInter930"
] | Methotrimeprazine | Insulin degludec | A phenothiazine with pharmacological activity similar to that of both chlorpromazine and promethazine. It has the histamine-antagonist properties of the antihistamines together with central nervous system effects resembling those of chlorpromazine. (From Martindale, The Extra Pharmacopoeia, 30th ed, p604) | Insulin degludec is an ultra-long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes.[A18561,A18562,A18563,A18564,A174934] Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide horm... | Moderate | 1 | [
[
[
9,
24,
1296
]
],
[
[
9,
63,
274
],
[
274,
23,
1296
]
],
[
[
9,
64,
1621
],
[
1621,
23,
1296
]
],
[
[
9,
63,
1411
],
[
1411,
24,
... | [
[
[
"Methotrimeprazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
]
],
[
[
"Methotrimeprazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phentol... | Methotrimeprazine may cause a moderate interaction that could exacerbate diseases when taken with Phentolamine and Phentolamine may cause a minor interaction that can limit clinical effects when taken with Insulin degludec
Methotrimeprazine may lead to a major life threatening interaction when taken with Potassium chlo... |
DB00978 | DB11921 | 739 | 1,019 | [
"DDInter1084",
"DDInter492"
] | Lomefloxacin | Deflazacort | Lomefloxacin is a fluoroquinolone antibiotic, used to treat bacterial infections including bronchitis and urinary tract infections (UTIs). Additionally, it has been employed for the prophylaxis of UTIs prior to surgery as well. | Deflazacort, also known as Emflaza, is a corticosteroid prodrug used as an agent to manage Duchenne Muscular Dystrophy (DMD). It is marketed by Marathon Pharmaceuticals and was approved in February 2017 by the FDA.[L6694,FDA label] Duchenne Muscular Dystrophy is an inherited disorder resulting from mutations of the dys... | Major | 2 | [
[
[
739,
25,
1019
]
],
[
[
739,
24,
1193
],
[
1193,
23,
1019
]
],
[
[
739,
25,
959
],
[
959,
24,
1019
]
],
[
[
739,
24,
1619
],
[
1619,
... | [
[
[
"Lomefloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deflazacort"
]
],
[
[
"Lomefloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zinc gluconate"
],
[
"Z... | Lomefloxacin may cause a moderate interaction that could exacerbate diseases when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Deflazacort
Lomefloxacin may lead to a major life threatening interaction when taken with Glipizide and Glipizide m... |
DB00622 | DB01259 | 1,081 | 392 | [
"DDInter1287",
"DDInter1024"
] | Nicardipine | Lapatinib | A potent calcium channel blockader with marked vasodilator action. It has antihypertensive properties and is effective in the treatment of angina and coronary spasms without showing cardiodepressant effects. It has also been used in the treatment of asthma and enhances the action of specific antineoplastic agents. [Pub... | Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. Lapatinib is a human epide... | Moderate | 1 | [
[
[
1081,
24,
392
]
],
[
[
1081,
6,
4973
],
[
4973,
45,
392
]
],
[
[
1081,
21,
28695
],
[
28695,
60,
392
]
],
[
[
1081,
63,
1010
],
[
1010... | [
[
[
"Nicardipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lapatinib"
]
],
[
[
"Nicardipine",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
... | Nicardipine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Lapatinib (Compound)
Nicardipine (Compound) causes Dyspnoea (Side Effect) and Dyspnoea (Side Effect) is caused by Lapatinib (Compound)
Nicardipine may cause a moderate interaction that could exacerbate diseases when taken with Mefloquine and Mefloqu... |
DB09065 | DB14723 | 760 | 159 | [
"DDInter424",
"DDInter1026"
] | Cobicistat | Larotrectinib | Cobicistat, marketed under the name Tybost (formerly GS-9350), indicated for treating infection with human immunodeficiency virus (HIV). Although it does not have any anti-HIV activity, cobicistat acts as a pharmacokinetic enhancer by inhibiting cytochrome P450 3A isoforms (CYP3A) and therefore increases the systemic e... | Larotrectinib is an orally administered inhibitor of tropomyosin receptor kinase (Trk), a receptor tyrosine kinase activated by neurotrophins which is mutated in a variety of cancer cell types and plays an important role in tumor cell growth and survival. Upon administration, larotrectinib binds to Trk, thereby prevent... | Major | 2 | [
[
[
760,
25,
159
]
],
[
[
760,
23,
907
],
[
907,
23,
159
]
],
[
[
760,
62,
479
],
[
479,
23,
159
]
],
[
[
760,
24,
466
],
[
466,
23,... | [
[
[
"Cobicistat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Larotrectinib"
]
],
[
[
"Cobicistat",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Doravirine"
],
[
"Doravirin... | Cobicistat may cause a minor interaction that can limit clinical effects when taken with Doravirine and Doravirine may cause a minor interaction that can limit clinical effects when taken with Larotrectinib
Cobicistat may cause a minor interaction that can limit clinical effects when taken with Donepezil and Donepezil ... |
DB08899 | DB08931 | 129 | 947 | [
"DDInter649",
"DDInter1600"
] | Enzalutamide | Riociguat | Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line ... | Riociguat is a soluble guanylate cyclase (sGC) agonist approved in the USA, Europe and several other regions for patients with group I PAH (pulmonary arterial hypertension) in WHO FC II or III; and for the treatment of patients with inoperable CTEPH (chronic thromboembolic pulmonary hypertension), or persistent/recurre... | Moderate | 1 | [
[
[
129,
24,
947
]
],
[
[
129,
63,
379
],
[
379,
24,
947
]
],
[
[
129,
64,
1478
],
[
1478,
24,
947
]
],
[
[
129,
25,
982
],
[
982,
6... | [
[
[
"Enzalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Riociguat"
]
],
[
[
"Enzalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rabeprazole"
],
... | Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Rabeprazole and Rabeprazole may cause a moderate interaction that could exacerbate diseases when taken with Riociguat
Enzalutamide may lead to a major life threatening interaction when taken with Ivacaftor and Ivacaftor may cau... |
DB00344 | DB11718 | 1,302 | 927 | [
"DDInter1543",
"DDInter640"
] | Protriptyline | Encorafenib | Protriptyline hydrochloride is a dibenzocycloheptene-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, protriptyline does not affect mood or arousal, but may ... | Encorafenib, also known as _BRAFTOVI_, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which impacts cell division, differentiation, and ... | Moderate | 1 | [
[
[
1302,
24,
927
]
],
[
[
1302,
23,
112
],
[
112,
23,
927
]
],
[
[
1302,
24,
659
],
[
659,
24,
927
]
],
[
[
1302,
40,
998
],
[
998,
... | [
[
[
"Protriptyline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
]
],
[
[
"Protriptyline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
... | Protriptyline may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Encorafenib
Protriptyline may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol a... |
DB00978 | DB06699 | 739 | 774 | [
"DDInter1084",
"DDInter493"
] | Lomefloxacin | Degarelix | Lomefloxacin is a fluoroquinolone antibiotic, used to treat bacterial infections including bronchitis and urinary tract infections (UTIs). Additionally, it has been employed for the prophylaxis of UTIs prior to surgery as well. | Degarelix is used for the treatment of advanced prostate cancer. Degarelix is a synthetic peptide derivative drug which binds to gonadotropin-releasing hormone (GnRH) receptors in the pituitary gland and blocks interaction with GnRH. This antagonism reduces luteinising hormone (LH) and follicle-stimulating hormone (FSH... | Moderate | 1 | [
[
[
739,
24,
774
]
],
[
[
739,
63,
521
],
[
521,
1,
774
]
],
[
[
739,
21,
29232
],
[
29232,
60,
774
]
],
[
[
739,
62,
112
],
[
112,
... | [
[
[
"Lomefloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Degarelix"
]
],
[
[
"Lomefloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Goserelin"
],
[
... | Lomefloxacin may cause a moderate interaction that could exacerbate diseases when taken with Goserelin and Goserelin (Compound) resembles Degarelix (Compound)
Lomefloxacin (Compound) causes Urticaria (Side Effect) and Urticaria (Side Effect) is caused by Degarelix (Compound)
Lomefloxacin may cause a minor interaction t... |
DB00279 | DB00726 | 1,152 | 1,164 | [
"DDInter1074",
"DDInter1876"
] | Liothyronine | Trimipramine | Liothyronine is a thyroidal hormone T3 which is normally produced by the thyroid gland in a ratio 4:1 when compared with T4: T3. Liothyronine is the active form of thyroxine which is composed in a basic chemical structure by a tyrosine with bound iodine. The exogenous liothyronine product was developed by King Pharmace... | Tricyclic antidepressant similar to imipramine, but with more antihistaminic and sedative properties. | Moderate | 1 | [
[
[
1152,
24,
1164
]
],
[
[
1152,
24,
1237
],
[
1237,
40,
1164
]
],
[
[
1152,
6,
4973
],
[
4973,
45,
1164
]
],
[
[
1152,
21,
28890
],
[
28... | [
[
[
"Liothyronine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trimipramine"
]
],
[
[
"Liothyronine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clomipramine"
],
... | Liothyronine may cause a moderate interaction that could exacerbate diseases when taken with Clomipramine and Clomipramine (Compound) resembles Trimipramine (Compound)
Liothyronine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Trimipramine (Compound)
Liothyronine (Compound) causes Myocardial infarction (Si... |
DB00047 | DB11255 | 176 | 1,371 | [
"DDInter932",
"DDInter374"
] | Insulin glargine | Chromium picolinate | Insulin glargine is a long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas t... | Chromium picolinate has a chemical formula CrPic3 and reddish-pink color. It is a coordination complex consisting of chromium(III) and picolinic acid. Chromium picolinate is used as a nutritional supplement for optimal insulin function in patients with Type 2 diabetes or promotion of weight loss. Chromium ions are show... | Moderate | 1 | [
[
[
176,
24,
1371
]
],
[
[
176,
24,
245
],
[
245,
24,
1371
]
],
[
[
176,
24,
1385
],
[
1385,
63,
1371
]
],
[
[
176,
24,
245
],
[
245,
... | [
[
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chromium picolinate"
]
],
[
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimep... | Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Chromium picolinate
Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken wit... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.